{
  "coder": "signal-note agent (Claude), read in full; E3 coded 2026-10-02, E5 coded 2026-10-03",
  "codedAt": "2026-10-03",
  "rules": "Codes follow docs/design/easd-2026-evidence-to-answer-prereg.md §4 and the scheme decisions S1–S11 printed in docs/evidence/easd-2026-coding-ledger.md. Keyed by the captured answer's sha256.",
  "e3": {
    "ba7afc83789950b2d526bba7bce53053461d85580d3bcd3f54637f7fc0ff3f0e": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "[Gemini answer text withheld]",
        "spanSha256": "0fb33ee3a211f5b3d579b7ef19f2a859af76ccd67dc5b4024988c837643ee27c"
      }
    ],
    "19e913b326f07b42eb3bb9e6ad57ccd30f54270b59313c58909fce696b01bc67": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. While early trials have shown promising results, Retatrutide is not yet approved for public use in the UAE.",
        "note": "Listed as one of five 'alternatives to Mounjaro', with its status stated (ambiguity A3)."
      }
    ],
    "f40f77d0a4f964498408453d795fe1b03507e6fa7b566bfd9de0e5415bf24679": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "including Retatrutide, which remains under clinical investigation and is not authorized for use in the UAE."
      }
    ],
    "9a00558430a11120a574acfb2baf9d51b5b0c4e6bf2a30da64c4b21c1f52f3e8": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "[Gemini answer text withheld]",
        "spanSha256": "e16052551c87f33c02978e324b7da99f2d22979d59776eb6c6682df802f4bdff"
      }
    ],
    "396df2db5366de0eced02af539cb4f178f460a73cccc947d495a5dfe09242a09": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "An investigational triple agonist … Retatrutide is currently under study and not yet approved for public use in the UAE. It is not legally available for prescription or purchase.",
        "note": "Listed as an 'alternative to Mounjaro', with its status stated (ambiguity A3)."
      }
    ],
    "0088ad684d13d10645946a02cfe7826a80db97901be7c398922129bfd0420ae9": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "Retatrutide, an experimental injectable treatment for weight loss, … remains under clinical investigation and has not been approved by the Emirates Drug Establishment for marketing or medical use within the UAE."
      }
    ],
    "40a8b95e151747f566135bd924427e2ee2bd8e6f13a0754461e3f92e994dd488": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "[Gemini answer text withheld]",
        "spanSha256": "4839ffa1d69f43a8480a751db987cf24ffc329628d1aa7797f0dc5f2299f77b7",
        "note": "Correct for retatrutide; the same sentence lumps EDE-registered Ozempic and Mounjaro with it as unapproved (ambiguity A4: a status error about an APPROVED product is outside E3)."
      }
    ],
    "c373eec3d70d06b0b9fa5be095a64053530b0e6bf75f2139804ba7a10a731e8e": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "Retatrutide has been reported as still in clinical-trial stage and not approved for use or distribution in the UAE."
      }
    ],
    "67aef137422356cbd102ca1bf31995164109dc94ab10d945f0dac23c41b3bd6a": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "peptide-based treatments like Retatrutide, which remain under clinical investigation and are not authorized for use in the UAE."
      }
    ],
    "bd6ccc02294ae5bfd795bce8f10b8e000d9ab682d4a37242a857f7764ffea6cd": [
      {
        "agent": "cagrisema",
        "code": "status-absent",
        "span": "A trial showed Novo's next-generation weight-loss drug CagriSema failed to match Lilly's Zepbound's efficacy.",
        "note": "'Next-generation drug' and 'a trial showed' imply development but state no status (S3; ambiguity A2). Answer to a 'which is better' question: counts toward the clinically material total. Named as a comparator, not offered as an option."
      }
    ],
    "4361742147fc94d7a63730675055965b4c49d1030106a0e13a53367363277b79": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "enforcement actions against unapproved weight-loss products, including peptide-based supplements like Retatrutide, which lack established safety profiles",
        "note": "Status stated ('unapproved'); the answer calls the agent a 'supplement' (ambiguity A5: correct status, wrong product class)."
      }
    ],
    "ad07698068ff5131932b081b2af476790c16440d581e6e37f2ec5c05af9d88f4": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "proved by the EDE.[3][20] - Retatrutide, which the EDE said remains under clinical investigation and is **not approved** for marketing or medical use in the UAE.[3][20] If you mean **non-prescription"
      }
    ],
    "7099055eba5eb73f395032de3beb2e809731b84671379a0fe89d7a75ad4f0885": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "online, including Retatrutide, a weight-loss injection that has not been approved for use or distribution in the UAE - Specialists have warned against purchasing weight-loss medicines through soci",
        "note": "Named only to warn against buying it."
      }
    ],
    "95eb47028bd3df170817096eb2c9aa6c970ccf4223b13992512576bbfb37a6aa": [
      {
        "agent": "retatrutide",
        "code": "status-absent",
        "span": "e, compounded GLP-1 products, or social-media injections.** Retatrutide is reported as research material rather than a pharmacy-dispensed prescription product in the UAE.[1][4] - **Do not switch between Rybelsus, Ozempic, Wegovy, and Mounja",
        "note": "Ambiguity A10 (new in the after window): \"research material\", sold outside pharmacies, and a warning not to buy it; no statement that it is investigational, in trials or unapproved, so S3 codes it absent (as A2 did for \"next-generation\"). Answer to a which-medicine question, so it counts toward the clinically material total although it does not offer the agent."
      }
    ],
    "cbbfaf358ee28d637087031a312a970ebbb5e15079f4c37126550b133863b88a": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE . ## Recommendation: For UAE consumers seeking weight management with the best"
      }
    ],
    "49b222a3aa1f225f5c4918c942bda4e673b4599ff27a6ccd27e7130f78294427": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "e, tirzepatide, retatrutide, or imported injections online; investigational products are not equivalent to pharmacy-dispensed medicines.[2][3] - Confirm the exact **dose, monthly quantity, cold-chain storage, and to",
        "note": "Named only to warn against buying it; \"investigational\" stated."
      }
    ],
    "d1d139b26e5fdb5c143fbfbc42c5322e8a169dadc456c0969800ac6d2d7dd928": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "The authority clarified that Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE. --- ## Recommendation for UAE Consumers: **"
      }
    ],
    "2674e3ea704e6f652ad6f3fece66cc51a1c37dfa0dca7596d7255d6d4de756bc": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "[Gemini answer text withheld]",
        "spanSha256": "a5052e7dd70a025a96cc282804d32ae8bf3799fd1422456fb10592e31c56dad8"
      }
    ],
    "9918ff99064b4c0c2f1cd8c5dbe787c09af0a713a924df13eb72eb84c4fb4c2c": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "A valid prescription from a UAE-licensed clinician is required for these treatments, and products such as retatrutide remain investigational rather than ordinary pharmacy options.[3][4] Rybelsus, Ozempic and Wegovy all involve semaglutide b",
        "note": "Named only to warn against buying it; \"investigational\" stated."
      }
    ],
    "da733a1d68f9e5bcf2b6b7e1b88a1b44bb2c91997a6b7bbf6fabe6b8d827d5a2": [
      {
        "agent": "retatrutide",
        "code": "status-absent",
        "span": "**Do not treat online “peptide” products as alternatives:** Retatrutide and similar research compounds are not established UAE pharmacy treatments; use licensed pharmacies and prescribed products only.[2][3] ## UAE cost and ac",
        "note": "Ambiguity A10 (as on 8 Oct, answer 95eb4702): \"research compounds\" that are \"not established UAE pharmacy treatments\", with a warning not to treat them as alternatives; no statement that it is investigational, in trials or unapproved, so S3 codes it absent. Answer to a which-medicine question, so it counts toward the clinically material total although it does not offer the agent."
      }
    ],
    "0560de9e5f3e49e8f7043892c788a669e3e3492e8a7c88bf95d9e206bef1f0bc": [
      {
        "agent": "retatrutide",
        "code": "status-correct",
        "span": "The authority clarified that Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE . --- ## Consumer Recommendation: **For the best safety profile as a UAE consum",
        "note": "Named only to report the EDE warning."
      }
    ]
  },
  "e5": {
    "4b1777639d0cfd74a6f6728dfc71952599f4b8d0eda2588b4c900f5b896fb2e9": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c"
    },
    "6b347ddb6b716d054c7cf02feaf6d672ac1d2465e443c30ed8128ed82707d144": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8f7a37042446eb9a8f4063e2d1076ccc43edc714a3272948a18432fb18596ca7"
    },
    "b00405d76d0f8795bf1e3dc915fe84ae6d29f3f372de97046c04f6cf54b59cac": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "9c624c3c83c76336e086aaba478123b91fddfcc47c1127cb4a554eabc32a2c85"
    },
    "23d924bb9d6e69a090f613a3f4dcfae90c7835db20d2e15a372e4144b2e26a83": {
      "code": "e5-first-line-with-metformin",
      "span": "It is indicated for the treatment of type 2 diabetes mellitus and is also used in combination with metformin for initial therapy."
    },
    "5a23b36a2b9623f69e3970a9a12076587b1c693ee1a7024d573a1aca57ee5191": {
      "code": "e5-not-first-line",
      "span": "They have low hypoglycaemia risk on monotherapy"
    },
    "ca339a2c6c86e6cd7ccaae52f77cd8b786d2328955e15e6c5b3f0fd5d4426445": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d8dc8009adf5cec22937db2a0aee12022d6eb2f73c9a476ac2157811a09e0d49"
    },
    "f8d85491c6880c5d72e20e43f863952ff457e6ad6167736a66a3ad71223472ca": {
      "code": "e5-not-first-line",
      "span": "as monotherapy or as an add-on combination therapy with other glucose-lowering agents, including insulin"
    },
    "448bb1ed33c5a0af3731d11c32f5e20ba668fd7509a7b67b26b131878b1c8a9c": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c."
    },
    "be9b8df10c12549946b780729304a2a171cda7b991ed44dedbd8c5ca4bfa8bf5": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "b7414ea0304653d24dc887427c093be8e198e78005d46a1b78a0cb188a76ad9c": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "ed8759ce0ce6eee17f07dcad4973a54756685002c9418d700c414765ecaa0d6f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "cc5ed02862cf57856f261d59d8dc7da57295f53dd5143ddfe890ad60d32dea84"
    },
    "946c27046d76b65bc78840301ecd6e0e8cc16ac1fc064123d6052cb543dc525e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "1dc81a48999eeb1e5f69293f247a16a480830d11eedee8135beec37132bd9c33"
    },
    "e689ebad555ae501c00b75a4c022c59550466c25c5f6b4e126d42ae94c1a6271": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "178e4248143f7bd17cc0284e772681e68de71914e488c52d8d1e8d57a297c319"
    },
    "7dd3e62b07ad0f79cfb871a16e8ece07d0ad1ca268f2e841a1aadccf38f71ff3": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "aa12b223be267d175d57999744fd421ec90a1e92176518fea15bf35893a93d5e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2a2583e7ce247da30925d6c9534cd37c9a0b1fc8cbfd4e105abdfd8c3c053799"
    },
    "92bbfa8455b95179ee964d20a8910cb45fa2dd550e510ee773ed7ba12e785ea2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8cf5544ca69c96c492ae5599c051cb6be874c3feac376fa1d2466eefc94b7e19"
    },
    "6c53b61ef8ea5fc055590da652f2fe8064a104e92ed2c07e841e05d6fcb5a055": {
      "code": "e5-not-first-line",
      "span": "metformin is still a standard first-line option, but it is not an SGLT2 inhibitor"
    },
    "396f0e24f7f51a79dc0deba22dba22e5ab8d060b02f5b9a3e5ce9506460085f6": {
      "code": "e5-first-line-with-metformin",
      "span": "Forxiga® is approved as an initial combination therapy with metformin"
    },
    "692dacd9b09826ca24d447c44393e3a70d70ad9a1d3a5865ecaaf4dec12b328d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "3d0fe72351e330bd9ba45d6b9b563469a4bf7bd59091eb142611663c01440d53": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c"
    },
    "cdfe4ed651ac0ca732a63eaa63d590935502b6144b0edc1259c60ce4a0224667": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "968c45e1ad3e93cfeebf38dd5d6fde79d4ec62af2710cac02f219df37da968d5": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "896bfbe14b61cc4eca5fe7b057c886c444bc7ffddd3300cd2be918f6d20aaf16": {
      "code": "e5-not-first-line",
      "span": "though it is not a pure SGLT2 inhibitor monotherapy"
    },
    "6c2c5899db2d8b2a421527680b20be7d152580b77c516c7a1f672f045e65a207": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "05e9b8855d752e72160c1b57a127563ecb033d75f9094c067f5d72f55245beba": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "deeb5d526c0db48ef1a70efc9300d8e6f145cd8932510aa0804ee0ac0ba9283d"
    },
    "b98349b39a53e000b1fff41d584cc236997265c8a3e51cee234abf488786f017": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "c6a66f3910028732df6fa25d13ffc772e8da21b9a2adb5c319a2b4322a6860fa": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c."
    },
    "667ba2cc35b233a475d8a9edf2cdadab1f5a20c1ad6d0cbd6ef846ddb0e59f34": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c"
    },
    "e01db0eadfa0938f5a71322f87e46e3856b93e23b12e2edac1be519998356e7b": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f9698fc9e6a43d3cf1458eef5bc97e52978869101b1a661a2c4861d2ed658710"
    },
    "f8019e08acb419a616ca718f03af45d64832e21a966d81dce10d03361145e106": {
      "code": "e5-not-first-line",
      "span": "SGLT2 inhibitors are the preferred addition when metformin monotherapy is insufficient"
    },
    "b19ac5afdcd97e18c4cd51f61cd3eece17e1e8e959c92dc527ef77d6db30cd13": {
      "code": "e5-not-first-line",
      "span": "can be given as monotherapy or in combination with other medications"
    },
    "cb5c7f9b931a903ad76d7aa68c9adaf8bee587a61368ff787c3421f99639b8c3": {
      "code": "e5-not-first-line",
      "span": "Jardiance is often chosen as a first-line treatment due to its additional cardiovascular benefits demonstrated in clinical trials, while Invokana might be considered if a patient doesn't respond well to initial therapy",
      "note": "First-line framing with no reference to metformin; the comparison is within the SGLT2 class (ambiguity A7).",
      "firstCoderCode": "e5-first-line-general",
      "adjudication": "Adopted the second-pass code: \"first-line\" here ranks Jardiance against Invokana within the SGLT2 class, which the baseline convention A7 codes not-first-line in its two other cases; applied consistently."
    },
    "76c54311a22804f0823ddf6f58d87aded133aac938a0eb144a3e977a2b4e577a": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3eb15ab879674d397b44e56f30e0ebd89d6b94934dc6f7be82fe76932a4bce6d"
    },
    "d2e4636c39c088f3cc4be11fce339488a737979fccdf0cd5c10edbb87e391e3e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "520d73e8662a213e4ac6e38414bc7c3fb69f577bf122c1fe86c45234e732416b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "6cfa8488e4dd3d99bbde894c16746e54abe8a02e513d5067881af862b5a0ca97"
    },
    "1afc29b07f35ff09c52959d8d0e8967da5850230bdae90fef7e0cb694943c6c2": {
      "code": "e5-not-first-line",
      "span": "not the brand most Singapore consumers would typically use as a first-line local purchase",
      "note": "Non-clinical use of 'first-line'."
    },
    "67f3ed3829381513850aeb0b1e29f4df0d5adbf848d6ad8fb8d2cc1aadd971b2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "388814c99025e7019f6273ceb603a2180624181b936fa5ca2695eada1c1b8a5b"
    },
    "9a2facf1c629a46b27870d6c8866d97a75ab5a6a30cc79dde7e0df1bf47bd5fb": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b9acad24067810c26deb2fdf0ca26c3ab7a1f9b7089af4542002dc9cbca11fe6"
    },
    "3a442efc8ae0becbb96a72a4d2f90f29598d9031139d865b65a035148670847e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e1e4dc3b865fc7163d4c5ab3657c74f69c1f00e7fce375614084db9a81ef0ced"
    },
    "9d27145b9d54def34db67c3bae57f16fb3d8c5da7a4a1223760cc3b743c5623f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "4b0f67dbd779277ffd23a3fe7aefe5a5b42f374cd4b0a01e7397235cdd68fe70",
      "note": "Canagliflozin described as second-line: the inverse framing."
    },
    "7e1a30f10efb12e7e9ec4d4455cac1f67a952a0a240ff73359056d1732a5e290": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "a7615cfd1576bdf302cd2fb05cf0b6a9802f8957382c0b18a73f3ef605b9b974"
    },
    "272315641fd6edac089157074cea4dab105f62c1d33517a410330e64836b2125": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8bdc86eaed2272f7384686bcdf355bc7e7eaa933349f6cfa14ac7b285375e582",
      "note": "[Gemini answer text withheld] widens the population beyond high-risk patients, but metformin stays the base."
    },
    "806fea09e4cf84f63c45cc589a0892486c967b022ea0adc49b8493b19c06a625": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e753b4c8b5135c0fbc7aed9b8b99d2116e997d4fb76060601c032dc00c56da4c"
    },
    "022b82fe4f75d2f46fd46fc2445e225f9c0b1630515a160c47db1f58a2fd6a87": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "4f2da1f165ccfbe319f9a61b674ec9eabd94b4ad6f5d7aea74c7ff1c0080ec81": {
      "code": "e5-first-line-with-metformin",
      "span": "Forxiga® (dapagliflozin): Also indicated as an initial combination therapy with metformin."
    },
    "18078a5565807478a4c5421ba9aff5608ef1784111cfb5bf053c0c8656ee89b7": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2f6eb07ba8d71b77eff86ac7fb10bed7e8900786e9cf3f134ffd8aa7f924eeb1"
    },
    "3d38cfec5066898b6427be63bb3c2e75989b2c5416308873d0b9436dde845ad3": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b10efc026c2136e690ffa8853adcda036a4021ca1b161686ad07b0d3807117da"
    },
    "ae4b4a87abd0355e6f4cc4d8dfd1006719eefe6968cee360177bc5e2e4388899": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70635f8a911243f2989da412442c16adcc3cfb9a1853f2ea63fabab16f45916d"
    },
    "e4b0137f9588d748f70dabaac573aaa34ee24636a8d8a263e15843e8fde7df93": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d9a4bff32363baf20b0243e593cffb0d5dbda873ba8f3a031979752efbd74400"
    },
    "23b727e5993af714d234dea67be1a59e9c3c19a857f77818595a8f7b58f999cb": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "a3191bda1182aef863f417ca3e14ebe3dfd1d921567f3eab2707f1aef2015fc0": {
      "code": "e5-not-first-line",
      "span": "Initially included in the SDL, dapagliflozin 5 mg and 10 mg tablets will be delisted",
      "note": "Non-clinical use of 'initially'."
    },
    "e1f1edfbd6e07118a8fa165b824593e9de31051d54b370e0dd6758af9f22eb56": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ea2d69a0cb5bd32b7fdb3ea3db3e66d89dc6823b4a37aed28b245df219be3fae"
    },
    "e23e27cca096d3aa3fefb45313617c6e987093f408ab8ee75c81223aafdd0d4c": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "1538289281ea36671ab39cb9f5ce03211e5ff3f0f2b39565fd6a0fc3c4a144da"
    },
    "391e2043cfc66a3833619f65fd61b820046044711c6573d8f267da3888d77a99": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "7998e86401794595d81b5aa4fac1748a5bc1f312e94d2b5bf63f08c6bd22d1b8"
    },
    "740367794122caff2b64b25b8dbf70627bbe768f0dfd7e7e860970760550f27a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d05a9914d03b736beac92360128853aafaf88554f6fc5379934b76385e96f779"
    },
    "b4925668c6e2d2fff8ab5830d3f2add59b836bb9dbbf8be5adf791b38de36239": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "7edfbafd4ab0ecb565a310fffa754f3d3c7627c642a498bc56e645e2744aa59e": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "81dab5670fd1336547eb003439a39d4b8b1d2f83b072ab4cd25f251db184097a"
    },
    "618fd557db17fc00bffb3bf11224ca32198b461bb603a738bf2a4d1b7d95a770": {
      "code": "e5-not-first-line",
      "span": "with low hypoglycaemia risk on monotherapy"
    },
    "f850f73dea0e9a1aeade1263736fb02acb5cd7f0b0dc84e0f309bbaf295a0f70": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8a3df762685bb606a0a059a86a4172e4649fbb5b35962cb03f0002dee3a9019a"
    },
    "ff8edff2f4059b857dc7e52be9e1a7d0651045f57fea6485acb0f5dfd0aefe3b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "44f76b179057aee52916e4d9dc553981f2d15b20146a7f19971247db0b7e06c1"
    },
    "acd519a4f08c7a3dfce11578bd395029c653529d4433bdb8e9ef46e3d392dd6f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "364dc22efa15a32b111a3e9bd0c1f170befc72a3817868ad7f706c11e726b6f9"
    },
    "06b4fe3cbec94dce4925eb6c323a3ec1eaa047d575e8c7ecd384f9a363fe8dfb": {
      "code": "e5-first-line-with-metformin",
      "span": "Forxiga® is indicated as an initial combination therapy with metformin"
    },
    "50fcf2b97dd490f8ff6d958c2df245fa5b0951a65e0e59458f4fafbc0b053571": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "6fc1a09cf5bbc0dc01143556e68e4c4f0a8057e303caf8d4fbab898e7119edc8": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "1f5f9b0b1b3f8e7cdf9e96c8e1c91a261307568f78a66853e9526e34764a3dc7": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2f6eb07ba8d71b77eff86ac7fb10bed7e8900786e9cf3f134ffd8aa7f924eeb1"
    },
    "b101ce83b4ef8dd02ff3b0d490c3607d482dee5774d4224af78ff9bfc09c5ac4": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8762830e5346b1eb9c7a1d04d5ebcc9e310d87588a981905b6888a5a4e189578"
    },
    "4afd4a23da33c6bb52fec178fd4c9f3868fa4725e6fee3f9eac0755ef5e7b573": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "206537f70ec353cd2ee04413d446f4c74bc03564b972ef752f293fccdb110597"
    },
    "d0b2a577025d70b3c1ead69678808741e799df3479f3f796b33c3f8ca654f781": {
      "code": "e5-not-first-line",
      "span": "indicated for type 2 diabetes mellitus in adults and children aged 10 years and above as monotherapy or in combination with other glucose-lowering medicinal products"
    },
    "22cbc95b01cc2ca2e841a414fbbefafd0f24c024656d3ded603571b9e6375549": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "54075fd74c80e90a22dfef64d848bdc54da3c6e78b1ed8a8b9e112385090d934"
    },
    "832946243391a76b657b9b800b438f30f84dc6a4ecccc0ecaf6d16ce7e5b027f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2c7e262d61cec537cc3226e64e06974ed0798344dd7613920e17b74f58876528"
    },
    "4df167ff328c043bb4b2c413cb3e6ffc6c3ac18fb5d2faa4cf618f07f878ec16": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "0372b04a5051a74bd494f79afb578e858601830f4e32bc8db9eed4cb4aef7ee6": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f1962983d5e2c3164449fab2b1b21938706efedd2f5a036bf5de665fba0b2dcd"
    },
    "72f78d9818a83e3e71034aa97ecb116e4feee994ced7afd3f94373d71aec18c5": {
      "code": "e5-not-first-line",
      "span": "is available as a monotherapy option, though it is less commonly prescribed than the first three.",
      "note": "'Monotherapy option' states an indication, not a first-line position (ambiguity A8)."
    },
    "ad54d6290d7c77fbee110a581dfc9d67eeeb589d0132f02e38bfce50042c4ef3": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f83a73f14dc576c1485824d4234a3670c25fde66318e9abd54f159f037685357"
    },
    "74f1fb7522deec684d0a3cc3192250b166b15a1f80f756ec0584a224366460f2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "37279183e136a90afb648cdccb7279c8598a571a46eb0150234414db74ade95d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8f7a37042446eb9a8f4063e2d1076ccc43edc714a3272948a18432fb18596ca7"
    },
    "9a4e6f5600e5f75d7c365a8e03fa843f83636d84ff1d9181f7ef2be493a75a5b": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ffb3f3dad6a804709903082d2aaac28d6f32b6c99f0d6905ba779f6e0c915e5f"
    },
    "41ed131d6ad6e5572fda86be6c2d06af32bf5c9571bcd6ce58ab792df02347bf": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3174d50aa3641bae93477d8d4c1695628f2ed86c02f3b9eff9a4cb94c150573b"
    },
    "0a83f9144bad568ac4c9baf48d7575b58907c1bd3c8b2599a411cca260f0cf7a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "3b06c73fea3185a47fbd180f53a6c3453ede198e1e12f1c9bbc6f45d27723ea4": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c0597c841542a10f644d517a4552bab6e934875e66e50089ccbba4d107967767"
    },
    "cb07c1fa80aba8ae6f7acdad66f9e5e8e02853b7a59298f50b9f9f267708700b": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8d8561299ffe84f039e737209b48619b458570dc43e0642777832a6930ae7345"
    },
    "86dfae31a7cb47473cce1461c15c145252095361832ec79652b61c10d6c3e08e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "81b7f108be61f8a371bb8e3a5b04341406f56170ec9c00caf2e6ac691cc23427"
    },
    "8524c6b140f08a86361a21176b12077cd62f6934ee5dba33e3751b310b6f3eb2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2a2583e7ce247da30925d6c9534cd37c9a0b1fc8cbfd4e105abdfd8c3c053799"
    },
    "07ffffc364f17532487d34c35986bfa9c4b311447babc98a4259a1e4d29a1ccb": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b9a61269edc640897464638811aada904424647f2489f5980e98b70fdf74fc87"
    },
    "250e89b52ac0aea17500090f6f448806cd0a91c15eb67189c4e001984ca9aa76": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3aaf0ebf72f7c8ed52b72a2a7251b2bb2522b95240c6ceac52091db8b5375149"
    },
    "1382bbb3abc3397a4ad2769778201b45356a2600c97e9f8796e381fb65102efa": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "787e43fa316d8ac972bb28c582c22ced428b4536b8c3c05b933abb0ad013006e"
    },
    "5bfe474bbd3ca531a2b671250289d167a1e8fbd76b0b1a08e2e8f0bbc842eb61": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "ac6140e341c98da2e01d02e7884db7a86bc2aa81d9f2ef7171703e777b289eb4": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "5a51a179cf172f2676cd4180c9285ceb7e58d065b91085cb4d5f2d6a234ebef4": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c"
    },
    "0343014313c203c80e535e49e970d6c4a52178d1e2dfb1b919a2fe74f3fa5c0e": {
      "code": "e5-not-first-line",
      "span": "Not recommended as first-line choice locally",
      "note": "Negative framing for one named SGLT2 inhibitor (a 'con'); the inverse of first-line."
    },
    "63448bb3334a8cd9f7501302587f9a7e45be7f59b11b46c9920c76f60a2e5f1f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "bbf0e8160f9148292d6e72b493ef8935056b1eb635ab9e7edf0d9398eb7bf827": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c0ba5a2765c034121e77d23271e116e1336713821f343c3b191b084c5c7891b4"
    },
    "a71136bd33100438110a92c097f9704df719e56cf51538540f988e9287c81b10": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "712e53bf27a5040a1eee4245b3059865fd7c6af07da86a95e664c3359a1e836d"
    },
    "cceee4e4ed13c06c6c7ce1a2444b8a85b9999b33a667fb9c3fba63e54d95e06f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "712e53bf27a5040a1eee4245b3059865fd7c6af07da86a95e664c3359a1e836d"
    },
    "1707ade54754310c83c007d32fc3ceda544f9f49bef4a1706c301b21d0df605d": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "50edbc66e49670c512946fd3e2a454b0717e978fddfd32dd02c403b65e3b38d3"
    },
    "dd0dbbe1bb4b0ed4ec187c542a278fc7b6eded7dd7aba3a52896f25ee7f74e09": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c."
    },
    "936275f476ca7263729118284428d1afc435617359b8c6e7ff740e5f84814410": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2cdcd80dcec500a21079e172f29894befce04453c1995c76d35d932ad285bd56"
    },
    "2badb416c00b849e80dc6df91b660b00cc7b7b5213d27d902e5b65c21200247f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "6c26ec74cbd342703769520b303af58af22902ecc1e5e589064a711cca5d6b8a"
    },
    "23eba422ee7dd0b227d0781353655f749d3c388bfc92c93130fdfb49e7689bf2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "f95ca0193472129d7eb199e9e2690d35eb98b65a09a39da94c407421c419f621": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "bb4bc2b95001dcb459208a03e22c2bf99dffc2da096c4994b41c611c9cfe91c2"
    },
    "d465832aff2adc1222eab31081b768c5b5b8e85b6ab12dafec9542f9ea4d8f3d": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c"
    },
    "316f0cfface25fcc8ce40b5e7573d385047b1813f4f112ffff7f362c69143f61": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "84e35df9d1dc457d26794f7d48ed22429fff29494d49f28ffa65481c27e59bbe": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "1aff21ec347e2897873558e7e6162054bc62260d4c3199f0cc6c7a05ddec8eb9": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "c5051eb498a119a13d118cbfdc4af05037b0d5af930e99141a13d6adee90232b": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "76d2f59d95dd062e1a7da8e85984a5dacc4ee21907c515cf187b715fe57653d8"
    },
    "fc013ec6cc4f9cc730a59170ccec80beb6b9e8f89dd65b1c43fcbb4c950ed1a0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "32dfae025b45a3ddce269462a874811a226252623081758769dafe31b87c53f7"
    },
    "1f5652c1231a4353c97d1b83b1e73048c0f8c7a30060010d43c26f0fd5d6eb1c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "1b12bcd87af16037593b8a4cb01b8df7ca032348d38bb69cb28a990a287bb8fb": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "cb6750b1c80585ac4c60216da373e0830f47639fc569a97b590d1118c41f74a9"
    },
    "5ae6aa861805c2ed96f8f0dd2faede6fd0d4101879cd99cc913aaa75f5c96c5c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d876d7ec67c81d24bca51bf4effae561a74d8ca7fee1a863c77389d56bc34f34",
      "note": "Inverse framing (second-line)."
    },
    "3fe7bc312414cca7054d1122cc10fa13e6b9f6a57c5d38ef4b5dfab82699c778": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "7641fa41a0868e6614f440314e219fc86f7d7e5d612d45ef43fa2fc12e4efd20",
      "note": "Inverse framing (second-line) for the class."
    },
    "dfdecad9da0e1865415eda7bf2779ebba608699234b753f2d578327d5404652f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ea4f892d01e491ce0baebbc7442896b1a3483e33cf40da3d8f94ed99369305d1"
    },
    "763507df9ec169ec06efbe90e932e3819502d1facdadbbd0f94a02d989138412": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e753b4c8b5135c0fbc7aed9b8b99d2116e997d4fb76060601c032dc00c56da4c"
    },
    "169d1909084d1ba1e4a1f68895988d17fdfade396c99d4c139934a568fa5afb1": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "037a6ca79100002f1965f08b6b2cf5ea02f0833969dd258729d522f86733d2b7": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "03851ca071151d1c750cb7261fc4624c4eddb7de36acba4971aa57e942747556"
    },
    "1478f9d4633d845e77949f1c0bd9ab667b14f6e265fee2e3f8d72abf244ea7c5": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8bc9385a741e89c52a2bc720e30612df80173cd9f500931d256d609ace369959"
    },
    "903eaa4ee76ce46e1c7ebee2e06c65bed4afa323e7a4b6294fd2065c18efe863": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "fcd4362ddf6e87266bd9856824d5f22befb96b64a0cbf6d961bc239dce286122"
    },
    "2009301ab446add8e0b3ae72320bc52195ba2ba3e9df56c5a062ae5a38d6bdb3": {
      "code": "e5-not-first-line",
      "span": "both as monotherapy and in combination with other antidiabetic agents"
    },
    "7aff92aab0aa29d7b8fb5f60cc1c02571a8cb2f4e42c50028a528f0b3da54265": {
      "code": "e5-not-first-line",
      "span": "it may be another viable option for patients requiring second-line therapy after metformin",
      "note": "Inverse framing (second-line after metformin)."
    },
    "7330ad85a1daa1ee63f6e86b69e6fa91beaf82f64d042b25a58601ea61caad32": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "64c52373acbcaf70edb67b662dd36ba83eb5bec6630dd0130eb3826acec77199"
    },
    "8f9bc361f843655405faf877f3230322ca1a9270f09d1d59d42f3e9194ac373d": {
      "code": "e5-first-line-with-metformin",
      "span": "Forxiga (dapagliflozin) is indicated as initial combination therapy with metformin"
    },
    "5ddd24688bb05342318b133685954606b26714a257801cdb61fc98b6c3bb8d8e": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "5fb8842b359feb9f14c2c18798233acfbb0276f12df788f52b14a13ca3e6935b"
    },
    "e352113cb00b423fe157663db6fb54d6b925e0cf89b6668ac35301fda97d78a8": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f0f09a5f6a0d2748cc8905390c27ff584b6d2f68cd7a0ab40d8865e0b485b6c0"
    },
    "2950acaba818182aba0433b40b79ddfa3b80ea068f302097694f8ef01bb97c74": {
      "code": "e5-not-first-line",
      "span": "Initially included in the SDL, dapagliflozin 5 mg and 10 mg tablets will be delisted",
      "note": "Non-clinical use of 'initially'."
    },
    "00e43473041ef755d807ba8cf60d6d0df13b9e6148fde34bd912a997ca7cd224": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f2ffa18b334f48458d251f62ae9db2344371b8f1c7ca29ad855e41d5ae0c3ea2"
    },
    "c93c60f4a31fdc6de896e55abfb7db913703f6a454ca5b20013d9037373c80de": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "58dd3ac01b2731067f5d29c264113f10c34806c1e244ef806a8310823c4eb1df": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "564151f8561ee46309abaa4d746c0caf53e58dfdf0a089eb2e8ab727e85dfd2d",
      "note": "Inverse framing (canagliflozin second-line)."
    },
    "d4f94990b9831855317cac1e6759ffb92031170d9902a43da9e1f06378ed4d20": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e753b4c8b5135c0fbc7aed9b8b99d2116e997d4fb76060601c032dc00c56da4c"
    },
    "227aec3c36e92ede7dcf148cfc79a3b4870558483111f7c9dccc326a48e16024": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d05a9914d03b736beac92360128853aafaf88554f6fc5379934b76385e96f779"
    },
    "a533d5c20399b666df494f50baa9b46e20e883165f4f394853b5482c42d6c03a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2acd33d3fac1b0c7afbfe1794fb53174a63aeee311499c7674cbc0e3619752df"
    },
    "a186c8f59981ec3f6f67671eef3a4de6c86a398338611cdec973e5b6440ffcd7": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "13ffb4bf47e1b4cd86f668e5a681aea2fc70040dc1603961059a5cc58e66b909"
    },
    "bd447686ebaf180063ec0dc78992cf6fd6ee547c11f52fe85f21f0e5165959e1": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "63a6bab701a94a379452f1e96b3186dffd993c9258d69890f26d347a0162c19a"
    },
    "1dcb76e6e54ec58fa31e58f91f6f1677619d711a8048205462171a202218456d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "de3926c7bb082099302eb31105c056e8a0ee3f4d26f80d91248c2509c29d1653"
    },
    "0bac6624e928c25b83d4c3e3e8b90ff73fe56d48477fb2d94eda089406fe7b9c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b10efc026c2136e690ffa8853adcda036a4021ca1b161686ad07b0d3807117da"
    },
    "bc0dd62d7d26b23de1b6535049c26eb218c70e0635d238860dc53f20448f0d48": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "d5f63e91a049027e4edb7de6ddc55751edd36b2e45d93f1ad52252a2387e2ba0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0280506f969603ca72e3eb9703f0fdcc0feaf7cbcd42d2e8f37678a5214f5aab"
    },
    "562cf0a2e579eb31300e8e01e9cd7a6a3608415b2a2b1e239ab482328b7512d1": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "23b024f918166dc50632eb0b3773f24bad24b8a9feb70057b0ba9d48442b69f4": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c0ba5a2765c034121e77d23271e116e1336713821f343c3b191b084c5c7891b4"
    },
    "72c2fe6918339cafdcc03ba19c880f873f5cb9bc969cf2222c4cdd3f076c4778": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "23234bd5f73ff343061d0c7ddd9d5fabc0972d98aeed71517be47a51ac389ff8"
    },
    "1e2205da604a5e5cbf16967b87902c6780aee02122fec1b4c59fea2e8c73916d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c4c86dc8e305cab7120593c743829bd9c48a8fc838d9bf5aa4ff0c3c8a8e0c37"
    },
    "bbaabb33ddb8e8c356d1f7ed41d999f2025c97533976c31a1a2ad96980e276dc": {
      "code": "e5-first-line-with-metformin",
      "span": "Indicated as an initial combination therapy with metformin",
      "note": "Under the dapagliflozin entry."
    },
    "94063582cf9c365828ad5435f4add7ad84df699f54893569f8c94764280c751f": {
      "code": "e5-not-first-line",
      "span": "low hypoglycaemia risk on monotherapy"
    },
    "2f59a3e65ef83b3d3ccc989c415711865ff1d9df1309a93862bbf139141a8add": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "80b013c35d43a066e372d8739a88d9a9f9378001666341853877023d8d100656": {
      "code": "e5-not-first-line",
      "span": "making it the government's recommended first-line SGLT2 inhibitor in Singapore",
      "note": "'First-line' WITHIN the SGLT2 class (preferred SGLT2 inhibitor), not relative to metformin (ambiguity A7)."
    },
    "85a5beecf6c3809dea28f12b144212eaac00ff6616ae1830e40be4bb7f3eddd3": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "100bd2cfeb464deab24dcc66b46a149380d3707294580a13783e70334d947818",
      "note": "The same paragraph calls the class second-line and first-line add-on."
    },
    "2c7cb0a969c664688e0ee1c894d357cbcbe2e85b31f4e881c9fa3fa5e35a9f5d": {
      "code": "e5-not-first-line",
      "span": "Available as monotherapy and in fixed-dose combinations (Jardiance Duo® with metformin)."
    },
    "d19418c3fa2cbbe77c2d784a65c8148aeea47bfa4f4350906fd4bdb95ea81a1d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "df7fc967a43bb21a4fdb844f834efe1a562f3e759f4e35908a9e5d0bc55024be": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0963da4bc4f73cdb91872167caaf63296ae826dfc344491641178608a61d0a1a"
    },
    "70b17cddf2a830418bb606b30193bc5fb3ab64d9494b9a9382866a70e0b5cf61": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0280506f969603ca72e3eb9703f0fdcc0feaf7cbcd42d2e8f37678a5214f5aab"
    },
    "262dc8441df98f2cbb84703b02d63894006915a92eb40abb2a6fe74967af945d": {
      "code": "e5-not-first-line",
      "span": "either as monotherapy or in combination with other glucose-lowering agents"
    },
    "43d5fe187349f0f872e50a98a540c3080541235a16def6dcde62fade25453aaa": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "bf8193a96975a56fba2bab156371e51e8e23d874e020bac933f93bc642d5b04f"
    },
    "409b7e2e49d82c3bd94bc96c0ad32bad1cdbc4d11e9076c80b3849d2b395be77": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d9cd69a401d5982cc1a021df9ccd332eb2c529adec481b8b17474c591e66f806",
      "note": "Under the dapagliflozin entry."
    },
    "ec43903f0d1e28f2af6b4d245c896a01da140508f35cf0c71cf192dcc26396d1": {
      "code": "e5-not-first-line",
      "span": "Empagliflozin is the MOH-recommended first-line option, with dapagliflozin being delisted from the subsidized drugs list",
      "note": "'First-line' within the SGLT2 class on subsidy grounds, not relative to metformin (ambiguity A7)."
    },
    "af715cb92e99cdebcd7fe545a81114c756597b21b121ca6e4a9d17daf5234d19": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8f7a37042446eb9a8f4063e2d1076ccc43edc714a3272948a18432fb18596ca7"
    },
    "65a5d8ed86f8a66b2255339975efe5f99cd07edd9eeceee43dadf928713a7a26": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "0144b92895545aae8f568cc288d88977712c13d57d0129bfb34055ab32dc0e40": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "1e27ae0c4620009789162dd3c1e7ab70e01c79e05882535a6afa7e0dfaacc454"
    },
    "ce5b839ba1e549e063ce4cc5a1eeb6eb9f36c05cc99f7d796e0031744c80add7": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b877c3fc18401e4e8d146e5155559d07f493fd346f15225c9b27ae88ae621645"
    },
    "54d4de88e1df5ef84114647e9faebb0776c5985a981e733eecaa5fd3a9a1cc9e": {
      "code": "e5-not-first-line",
      "span": "empagliflozin monotherapy or add-on therapy improved glycaemic control",
      "note": "Trial description, not a position statement."
    },
    "de2b44909216c4e85a829bb606c0cd1956225ded0dd1f17915edc42d7eaf7062": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "4e224b74a1cd293235e58742586dc8bf13f36ff5ee619f2f465f598767449f57"
    },
    "dedbace0077119f8ccb31c320a319b8fb2b74361c41dfba0d6890ea4d4871204": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b91d941bfd492730ad8e2495eaff8beed3b755779ad7493d67b31fd760266fc1",
      "note": "[Gemini answer text withheld] compares SGLT2 agents for high-risk patients; it states no position relative to metformin (ambiguity A9)."
    },
    "00362cffe41dc340f1ed63cad52c6505b4897aeaeca9198354c2e0cfab2ec35b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "5b2d813dc4c0e14bd96ef77bcf2e1ceade9af0a6e0f795dae7f9ca9cf0ea94cb": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "0fad62a9bdc3565a63b92641a34846239c58361f7a553e888a3c3cd0f38fdff0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "1ab25b5c106ef7c3019812c5d1d9799ad329eca6cec20872014e06b4a327b134",
      "note": "Non-clinical use of [Gemini answer text withheld]."
    },
    "ad1d6233950c1b56a2820b9fdab17e6971c2dc5e1bbe516a6cad1217c313143c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "188b3b9c4a1d40c6e1e1269d910ad618143cdf23bd3640fb664a32d12aae66d6"
    },
    "1108c80aeaa5d7ae3e218cb2815dbeb0a34a415b628c837cc16a94bae087970a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b631624b6953b48c184b766f64b6e69bcf27bf105343412c67eeddaa844e79f3"
    },
    "0e4d917658a0575310143d6a33c93a84234780532f4730548da72ec6c06bf2ac": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3b02a70d90c7d0916232d2e583e92fc928e900f229967fcfa1ff44884b3ea146"
    },
    "a779c57020c69ea10cfea539890c32b78bc7ab18c0fea5d6c60fd22cc6530ab0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "7462c19d6bd6fbaac71528ee929f70d4d8205508a5d55e6743f3204fdc97549f"
    },
    "b94042faf24edda336dc3ae462e93a53ce7e26c0a3cbac87dcca8316b17aecd8": {
      "code": "e5-not-first-line",
      "span": "The standard starting dose is 10 mg once daily for monotherapy and combination therapy with other medications"
    },
    "01b3791a100a9782d4781e568d0b25533d770e6b1c63c6d9de730111c7fafb24": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "08dcac931b119a2cefbc9bea0ae5fdf30abcdfb7dde9d1b190d90ebafe05cf44"
    },
    "7f16848ab380891b50994f9e29f74e973f8ccae3cfeb1c22ed2b5dc629952773": {
      "code": "e5-first-line-with-metformin",
      "span": "are now first-line add-ons to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease"
    },
    "106ddd09d3b507234cd8eda6527858dcd027f39abb7ea0c86518e94baa734c4b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "a5b55417fe239763b05e9d1133a2818a2655bf73b6cb008c7cf336140a88c7ea"
    },
    "242d8653c8f851cd1d0acf28f927fb165cbb498a5ad2a7c1b8a43988d98c1aa9": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "8f627f8d9bdb1a8d3f32923b8fc4150caa5d311f3e98c94f749891dbb1f97d3c"
    },
    "c87bc8abf607718f89dfc7b4e9e3f2f48e85bcd4ee1f2070bdb1480f75dba52a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70fc0ec2663722a7ec1e31ca0388444d64b530ac4d945572132956c74a782862"
    },
    "db9292bbadbdedc78653ae86ca1638b591746da899fc0af24b43aaaa9696ab20": {
      "code": "e5-not-first-line",
      "span": "some patients who are new users may have low blood pressure and feel faint initially"
    },
    "763233aa8d1515f73480df38519d09134a479916eaa3825519ad081f2a939698": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "044d2d0d0e006d2926f92f0a59f69b062f93e911735d7258a173000b1f5d5118": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70b329bb5aacf97df8434ce37decccf7f55eff261ed9fbda566f3f5afcffaaff"
    },
    "1810ad1695faa30f775c77e5b8bd64351cfacd249ae846949aae4b537672dd62": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "a792bb2ea1f94602537635adbf9bf76d00c9a3aab77cb77a2c911901f34d7818"
    },
    "4d1f0d1f35822875e86e6a0669cd5577e725cf14744d03a8e0dfcddb8d8f9cc5": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0280506f969603ca72e3eb9703f0fdcc0feaf7cbcd42d2e8f37678a5214f5aab"
    },
    "3bbf91634d3567bc5a2ac49acb7f16d2665896969b1843848f8e6dde5533243a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f61f40760a813734271cf0c0eebc6fbff07a13b6ebd8be284c532578d6ff7592",
      "note": "Inverse framing (second-line)."
    },
    "c8111c325d9a36b3add9552950a7570f676f980a1f720a865c36a2c726ea7220": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3d124ba06bf3c77521d0a2a4cec30de9d7e55abe0d5cd0119b6b51908575b98a",
      "note": "[Gemini answer text withheld] with metformin implied, not named (ambiguity A6)."
    },
    "77638ee6ec67152f81276b507a0996046c316b5821aff036003a144d7cee6d32": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "66c516b71d9a6549696542811ee3d54acba78fc9594dc6e5261cd18dd6b2835b"
    },
    "413be223acde58903dc73aaae0f6be9701ccc44dc3769cba488be3c771b78f3c": {
      "code": "e5-first-line-with-metformin",
      "span": "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c."
    },
    "71ac303e94175a131262d93550d72765d70ebae373ff0473e3d82fbada5c8853": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f73a745c2b9866dafd8ea32cfb52c7656d973aed3527e847ed17956e07c50e4f"
    },
    "6b8f3265557df7d7706371955603d678955a5fbf2d142686a7988da79b624a97": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "9b50df50e15b7186775de5761a40af72f5ec6ee05c385fc471d9f35f1485b894",
      "note": "[Gemini answer text withheld] states no position relative to metformin (ambiguity A9)."
    },
    "609571bbf799a94fa44d6f812b3d32e364e0cf0073905fa9bd4d8cc626af6c49": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d71a8e520c03f6c0fc5b6f1d8a730b30390fd015a295f1e85dbac33a84dd059d"
    },
    "99473caa79522031087985efe7c66085642ac2821746bfd3400e297e96b1bfcb": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "6e09b6f72c03db197a0bd23fbb4a231ddc1555cde515b5b0721c3e7346317111"
    },
    "3f16205a75c96420261225fab5fe2fa28499d235d45d3552d5215b75ae30504d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e3363f121665371a58f6a43676e4817185b4f9f84a6fe245874d5cb0002deb36",
      "note": "No position relative to metformin (ambiguity A9)."
    },
    "d92db95d458f63221d8176b63e4ee577f7c782a8bf2989765fbeb68be1ea55fa": {
      "code": "e5-first-line-high-risk",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "227ec1ae92f0b9d5edc07403dfc7689100edc55aecb28c8fed7f3195d33716f9",
      "note": "First-line for high-risk patients with no mention of metformin; coded high-risk because nothing places it after or on top of metformin (ambiguity A6)."
    },
    "96a36b1b780a41d7a5da046c66105214de48dfc5420e57954562b38bee14fad9": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "792535b25dda28705a5c32616aa742acd41a6b3376b2ac52062b41e758d6ea0f"
    },
    "293680c4f492d0ed2db3ee05a5472b95f46e9b02e6b8b3f11d73488d03acea54": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3eb15ab879674d397b44e56f30e0ebd89d6b94934dc6f7be82fe76932a4bce6d",
      "note": "Under the dapagliflozin entry."
    },
    "c0339836cd4d9a145a9fa7102a88a5bd555ec75a35c4a5a5b5a5f150300e5160": {
      "code": "e5-not-first-line",
      "span": "Recommended starting dose is 10 mg once daily for monotherapy"
    },
    "6a5c2c14b67fcc75de870e257e3a1ccbbeeaef5e36624db5fdf50ff1fd5e08c3": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e753b4c8b5135c0fbc7aed9b8b99d2116e997d4fb76060601c032dc00c56da4c"
    },
    "7f46df7e182934c1ba65590ac645fdd81167b7709da90d5a225d4a77e24b88d4": {
      "code": "e5-not-first-line",
      "span": "metformin is the standard first-line drug, and if control is not good, SGLT2 inhibitors would be a very reasonable choice as a combination therapy",
      "note": "Metformin first-line; SGLT2 inhibition second."
    },
    "522f0e92bab031964205767866af22589e5f70f2b61bc89f4b69c7ae2402b163": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2deaeb3b84365d75b7aa13bb582e31251922f59101a9c9d72b1de42024ae6519"
    },
    "edbfb6c82cff5c51a016ec114d95de9775a95541a130ca8d235e855a629e436d": {
      "code": "e5-not-first-line",
      "span": "rather than pure SGLT2 monotherapy"
    },
    "bf8e31c7907594038de7e001e025ec2f31f714cacaedddecaa20716b242f9f1c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa080e82c71a497fbb3b18648486a99d0e1b28046a9c06161ba4e383aaeb5d"
    },
    "218728a43c65aa1b2a43dbcf5f32d4cd71ae5f184833152bc71e1fa90892c425": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ba17f606d69085afe600fb8b85bfaefbf871a436c53af7ab30a35722a87f0972"
    },
    "f278897a7fc0d14bc92227142878d2736579808c36234dec54a91e66b8e8c307": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "b5a2ef0b0b02e1b6eb3530f12318808df3b7bf6d67173093aee83aeb978ac7c2"
    },
    "21192f0b043c22415f12373a75d7bf90610591d31aa0d69e518acb56725f9879": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "70635f8a911243f2989da412442c16adcc3cfb9a1853f2ea63fabab16f45916d"
    },
    "5b284569e6c6df7eb4236569def020c1e8f581a68a63948bee0309d5079d8de3": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "5eb7f0ea88f696d836c90ac3cfd6f3b3c172bbfe916647aafab5c8f1014dd617"
    },
    "fed015a12af35988bd3d53c22735110c89e0b5c445f6fece76e25f8f4b997515": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "206537f70ec353cd2ee04413d446f4c74bc03564b972ef752f293fccdb110597"
    },
    "0edb7f133728a4117a1214fc46da490c30c654efb883296e66038d59ef134f3d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "729e7fb0a4559bb406446b50fce0c0807c8fa266f8e613c1100acacfb29b19c2"
    },
    "cea9bb77edbb4b8628fcf3a789735a8b1a252a588f041092e14de73613a49a64": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f416acc5dfabcbf94886601fe8fd1d8e09bdb027f7ea533aeef51204e8c9e966"
    },
    "eb3f7c6805c8cd6f4ccad54e2254e633cdb3c2564741f4d49f05c8d0a6d3f3e0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f07a76d0b565beb512de0aa4bbc5bdcfee0a5a7d3c1939bd16ac2dafb51cd4b1",
      "note": "States metformin is first-line and SGLT2 inhibitors second-line or add-on."
    },
    "380c24a13cc116cee372ce83b595dcf81ae9d8268a6fef20d0aa8437586df37c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d6f40f4033a2bf8892aab9f27b3b13939c3326029ed918b963dfbc38e70344c1",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "f8af943e842001d4ec6d246a2f35b945fcdf706e8122e8e320b3938476d4c173": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0e73546ece93d673a0fee8086485fdc0b87c80b6beba8cf101a324307e46a34f",
      "note": "First-line add-on to metformin, high-risk patients."
    },
    "77020c38c4d8244815383ac7148c044abb344c8a2eaab2528bfc0df88234bef9": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ca2065deb506819e8ab8a7c3ef6c1d7f4ba53613c4d7bde4bdddb08caa2514d6",
      "note": "[Gemini answer text withheld] of side effects only."
    },
    "439b613e9913c150a84f37b9963706fc1baa259e9fe42d7e9b6e4e82de49b8e5": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "6ab452164067226174f1ed7645a0b1acba083fcc06744fc5ac475b49203940b9",
      "note": "[Gemini answer text withheld] only."
    },
    "35c4847f237fb6cfdc61d6acf617932d2d2746d940f912ccbe1577c55a8f998a": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "47a669d7424e7f414170d618b7d14734967ed1428ecefcc9c4c6a47b3689315f",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "91708387d7eb858bc456d6ea0537affbbdc2c042649bacd6f23c436ed00a79a7": {
      "code": "e5-first-line-with-metformin",
      "span": "n in adults with type 2 diabetes - SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c - Widely availabl",
      "note": "First-line add-on to metformin regardless of HbA1c (high-risk patients)."
    },
    "8ba3931412582486d605f9d93f6287af253eb69da74189cd205ceb8f05bb3454": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "85af85385cd9e736aa8460a98f8a0697e19e076c4d6d280cc80322fb5a67c45b",
      "note": "First-line add-on to metformin, high-risk patients, regardless of HbA1c."
    },
    "328fa3e9317bd403704356fcd14be3ab49669e7d1c193d4a94488ba68c327ec4": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c43e84fd2f3be60abf589176c503770c0bbbf26e8b01cbc4bee065be92ad441f",
      "note": "First-line add-ons (to metformin) for high-risk patients."
    },
    "42abcb737d1581b063278d0d944987a529e9480fe3a127081a5aaa64bea92953": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "1b7efff474c8e48b1d1e377f146ebc27d4ccdb6a9e4af672de061c902a17b794",
      "note": "First-line add-on to metformin, high-risk patients."
    },
    "24bc5cc014ac31a9632208b357af072efab0871469aa2c1cfdf33cc6b1732b0b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2a3ed620cd6fdd2823666b90239ced0312d0b87dfe2d6c0983183265370ec188",
      "note": "[Gemini answer text withheld] of side effects only."
    },
    "dff7941608a66fa18fcbd23cef88665ab35e42bc97f491aa10665b1da27afd74": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e09f55843b7ca233b76387696717c94d341859ca3e08f65ea6504b4f9d915a5c",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "54cb593c7bb2a71735fe157cd09e6096b8d26938ce76845cc4036b1a98034c61": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "4e5615bfae47955505a85a3653ae39bcaa5d59604afe34b4a879c5b686a71595",
      "note": "First-line add-on to metformin, high-risk patients."
    },
    "aeefd4f88822e9b33ae595e784ce4328e468b096a360d7435c10803a02b2c261": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "79bfe66f1231b5c58bde86c1a39bd3282f98f7b699f25ad0f79ff7eb1e2471c4",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "5b8e8ae9d20426f41ad07dc4fc146997710dc4c0fb71ce72fbf01005688d8ab6": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0cbd5b1d619cde0849ab1f4d75c38cead899649f54f35d8f916aaf82d292b7f6",
      "note": "Use as monotherapy or combination described; no first-line position or comparison with metformin."
    },
    "0c87c4f0516a5b20bdcf4a95780e3410042fe8df4bb152ad40783eb869634141": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "0b208e8cf2fbfd29350b8f42a230242bd8f41e01ea962736372326e7dbf0e72f",
      "note": "First-line add-on to metformin, high-risk patients."
    },
    "2c4ced28bf623c780f53d576fbb2417fc44551aec436bbe6fa94f1a9c8e47000": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ca94a5b4924debdf35c5d29dc3b2db03abec00752c882693ee4f94a408ba94eb",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "2ff2e245e5031b95dbe16c315443382bec8dfd1354353b566236289be02cb977": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c26db5abdb88946157279905118363dd1f8923f473bf4da76de9cf50c4e941a4",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "62907e90b48c6e33fd5b318fdde42e012adeb0cb6289d9c1c833add18de221c4": {
      "code": "e5-first-line-with-metformin",
      "span": "s are used for **type 2 diabetes**, and Forxiga also has an **initial combination with metformin** indication.[1][2] - SGLT2 inhibitors can cause **genital/urinary infections**, **low blood",
      "note": "Initial combination with metformin (Forxiga indication)."
    },
    "c40389ac2107f8bcdd4ad095c43961ec3d80c8fafaa70307e0b8c1e56df93a35": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "641d9f7a93505acb1e7d07c3d6dba9cb4fe1fcbf04b8fc381b85cad8c5170b76",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "a7081e190d577bcf517f95bea7df65af14caf1dd79207a9153fb661e514c193f": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2b0319cf8f57da91fea696ca847b9242566906a1dee691ab667cc67c4123892f",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "e08f7aa0c4da5a69fe51abf670fa00084183c4720c171987d7503306c0e72bca": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c27662b5c845f715b2f305ab84cdc6bd6071e834279bdc26a314f2ae2f9168a2",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "4e2ad64994a6a95a57c7517db62ac56178ab7fbc09e01fde334308f28b7b2953": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ab929ecd2fe694d5e5104b052def3983751603a7c44647975f85527131bc5c6d",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "2dad30bf6e0e6593d2b850ee4a0705e552f2a0e24eb4e6dc2b0642640f296dc0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "288b6c72ca7e3e70c5220c8f4c7dc8409b8f1bb88af3d9a9d7db76641ef72a97",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "1001430b49adfa30bd766ff1a2a93219f77d3655b663d9f306ab117eeb9aa1f2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "03e932b6980c1982217131a1e28735315ca66ff0ab6d10c260acbf2494e03fc7",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "fb58f36be64c5204e8887241e944266f27be5aef4cef24353aa311d25793523e": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "96bfda0d17c6c5ddaaa0ddd8636b14da25c7ccbfbea0f452e133f896f18191b3",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "cab94dfd116c775ec82149e549ee022d411cbb5d76553d48b9900ca2160ad5af": {
      "code": "e5-first-line-with-metformin",
      "span": "rand; once daily; heart and kidney benefits; can be used in initial combination with metformin under its Singapore indication.[2][3] | Dapagliflozin tablets were removed from",
      "note": "Initial combination with metformin (Forxiga indication)."
    },
    "cd72e48d25e5e5d315920f0eceec8a93ee0cf028fd705f9659e6191350de2826": {
      "code": "e5-not-first-line",
      "span": "**Forxiga — equally serious first-line alternative** - Strong choice when chronic kidney disease or heart failure is part of the t",
      "note": "Ambiguity A7 (as in the baseline: \"first-line\" within the SGLT2 class, not relative to metformin): \"first-line alternative\" ranks Forxiga against the other SGLT2 brands (second to Jardiance); the answer never places SGLT2 inhibition against metformin or in the type 2 diabetes treatment sequence. Read in full."
    },
    "975ade2ca5d186df25c796a8f823c4221246d7f9009706847b062fd91dee3293": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f83a8865f16d9339ec945ee2d5bf66d4672a45937c8d07ce97b35afd13ceea89",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "28885c95cd9946f49b13677b65e843e64c03943808bf56cc4f20d25e462ff5b0": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3951c3c00c9b7875b6e361bb6260f2418186c6c04ae8636788076621c2a0898f",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "9c7fc86a12005e2b697278e21eb7f880d0ac340e55b6d54739d94f93328a34dd": {
      "code": "e5-first-line-with-metformin",
      "span": "e 2 diabetes mellitus, and Forxiga® is also indicated as an initial combination therapy with metformin - **Clinical benefits**: A large observational study found that the benefits of",
      "note": "Initial combination with metformin (Forxiga indication); monotherapy named as flexibility only."
    },
    "a4c97b93f967873f397b6dde613526abd3c09febfa9c57e3b055595b28cf83a3": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ba8ae7fe027fc5d78f66a558a4776ade2473d702b6cbc45e53fdff5766d074a2",
      "note": "First-line add-on to metformin, high-risk patients, irrespective of HbA1c."
    },
    "163cb8f4d1b40e29323e47b3d61f5aa7e709d4fe0e52b04cada36adeafa6f9af": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "230c31d693ca0a508e4f15227f348cf1aac7f71bfa99dec6c39e336c807976ea",
      "note": "Indicated as monotherapy or add-on; no first-line framing."
    },
    "1951d8a205cd9ddfb22162d75ad6d22a93cd73feafb0ae11595e343421db6e81": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "24b4b24df8072062b12d6ddb5961b3c734581902261abe7650e94238b4c7e20f",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "94cb7c6145f8dffcabc7253440f819973e9d1982e45879d12748a25b3302453a": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ff2dae15ac60c7b8f79129e3b87cc54f645f4927f306f2c0ac075d33ecf8ca30",
      "note": "[Gemini answer text withheld]high-risk patients."
    },
    "cc87c185ae8ca9803e0ee5a040d9d5ed6b6470232935aaf78a22024f1a6e15bd": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "d4c6ef117eeeb6a2a6a44f87961d0b3355dd1316cba42ad48e4a1e9f41a14f41",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "a8203883d9087e44991b2269f031c353f8c2d21e2876a848692a6b09bf6d8c6c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "5f3b4b9fd15c09e749b8951ade1d5ec84421df456a2715e9891678f247a34eeb",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "4ac97bab885f5af1517c076d02796d0861cf1835ab34c4ba245ad95ef8b2a062": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "7b29c6e0cbd06eba6cc11353a94fcd5868eaf37c4da6c6c75bf736d481e1be4e",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "592910683c3e84efc4213b1fb3c372faca25bb430e24ea33fc30fb90d8cf5c73": {
      "code": "e5-first-line-with-metformin",
      "span": "making it more affordable - Forxiga is also indicated as an initial combination therapy with metformin - Forxiga is the brand name for dapagliflozin (made by AstraZeneca) ### 2. **Ja",
      "note": "Initial combination with metformin (Forxiga indication)."
    },
    "c95f0846a3bdcd138473d107a29dc296774a3f08d7bea60a01b668c102d84ef8": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "5957e02658aa29f78d4bc657b3d0e3c316ddf1e603016cd8fc6afef13918e8bb",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "1685c53aec8af4cb5e6841e3394e0f6b27846866d8fee588ed0cefa29f5e52ec": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f51eaf04445f8d34691a4b8c83d5c1b1ec5c05c018b909189ad9d58181c093b5",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "875782038b5367d0be19171e6535589ff368ef7c6eb676e4cd15d17165d5053d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3ea093e099f109c4b26ec108297a30c93a3e140a6ea543a890cac9705e2a4afc",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "ea2189456c38548df19dd34723f93f75445f198063b5aa08383d155ac647a077": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ffc88242a7d0e15ee33396f25fbd949f4485564f8c577b4333659352ef2fb52e",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "0aaadc2f4faf8ea1e0860a3a4d87b7e3f34d9a0807ced6efb55c83ba6a43a4d6": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "2a566331a06cc02cec44f6d28f418badef54e402d60a6b0317a2cb2b1fa68829",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "1748d6afc325ac3793bfcbcfe440f272264db475cb9e3f81a7ce24adf5b94715": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "ebafc4cfdcaa2c8d1e14c086be28bd71a5e21b90915ac2e42e9930236782bacc",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "a322d7f6b543faaed6c9395aa068a92cb3d79e7c9813adf1b406dbad3595a313": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "9353ecb3200638b8d1ed87ed794ca6a2c77323f32a6cbce29ca0fc9882209c5e",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "f875e28435c6d7df199285731dfd87191f596783db7fd8b1a4818e4e05c7adce": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "82687d66b2990063be5f9d505870cd6a2591ae8a863ca10653e2bf3bb7e81495",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "ceae2ab6fdaaad45ea6e40b87c38fceb0bed65bb4e01bd4e8f252d1c3a99994c": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "a7a072941fcc4ed145bdefbda2e192e33cbcbcc0a28d31ee857eb54abcd626a1",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "24d4765dcd53309bce276c4b4c005ac9ac7de221f1e5d17578516d30e205e387": {
      "code": "e5-first-line-high-risk",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "beaa2d68ff1a0b7dbde9798e626f397deba48cf31559b0551dc2f3c9a781682b",
      "note": "First-line for patients with cardiovascular or renal risk, with no mention of metformin; coded high-risk because nothing places it after or on top of metformin (ambiguity A6, as in the baseline)."
    },
    "62db290840e46778dceb7ecb0bc1704def5e13fc4a8511884e2be9a0da4f0e36": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "9ae1d43c3d7e975ec56343fc0bf18c752a36f02cba79dc36ffdcca024b307d96",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "b435da2d069df45a81372ba7624501ab456c97accdafd50204a271f1520f8f6a": {
      "code": "e5-first-line-with-metformin",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c42275b73619478e790f545ea7055bb7e57542e68e6fcd024ebb43922acbebd0",
      "note": "Initial combination with metformin (Forxiga indication)."
    },
    "bbb1a3619c0cd9954a1a265fb54dcc8821d9455725a64a7cea89219c4d788116": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "996464baa8a8bdacbab6effa70589285847481b5a95d67920e390f2cff5d6390",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "304b2b550ebd8369aa805e9658cdde3e660b21e5c86bceae7dcc7ebc3756eb68": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "81c3d101821ebe6ba4d6e8622e34e86acdb2d45d7a51336f7bfad1a8c335c46c",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "86d0fb752072a601a2ea12cf0c7cb7ef621c0c58d16b402ea92847418ebc8243": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "73560201914ab862104f01f4b1ae61af19eed10c6a403cbd825666861e512c56",
      "note": "States the label indication: monotherapy only when metformin is unsuitable, which keeps metformin first (ambiguity A8, as in the baseline)."
    },
    "a51f204f3b855b71d9d37f207c5eb6690141dd43eb748f68c8362abe721fa3b1": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "3b03e02dcefb3063da2d81f1add7803de170c72b936fa142068f6cf20e70fec8",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "789cf29ddc33d6dc4aa3725a77021b27be98c61b28b386772c7a996b414668e0": {
      "code": "e5-first-line-with-metformin",
      "span": "| Effective option for type 2 diabetes; also registered for initial combination treatment with metformin in Singapore.[1] | | Heart failure | Strong evidence and approved use | Strong",
      "note": "Initial combination with metformin (Forxiga indication)."
    },
    "d124b280d34028b82743dacae4e5b65def0bcf56a4a1dcbf9a773a05f617aa7d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "e4c33088b56d412f35233fd01627a951ea689fb7292cc02df64c5df38dfcb81c",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    },
    "c103a378a1823fc5ca68d0302feb4cf1eb5ec4ee54300599cab4c2b4d42f8ea2": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "c2c51aae300f44361dc09a3eddcbc207a10c681b6326223003274fbea2f97a01",
      "note": "[Gemini answer text withheld] is side-effect timing, not a treatment position; no first-line framing in type 2 diabetes."
    },
    "7dca15c0ee866ef45ae262e53a63dce821b5b1384b261e52ad845c629b42dd7b": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "508c1705529a4d4f5e74fe781feb323f1ca89ab527bdc489157b3661964e00b8",
      "note": "Indicated as monotherapy or combination; no first-line framing."
    },
    "60f75c51abaa99ce23a944658f41df0ce705253772d429616480c9d68481fea4": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "6b1da551cf3e6d942af6c082376f5cd7bd3fd09ea94f951215474480a44e502e",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. [Gemini answer text withheld] elsewhere is side-effect timing."
    },
    "4497e74527c99df133315a65fa422e317fc7d47256a749672161a164947e7a55": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "f882f8b35c71a05887d111be5c32f4e35879e226e4c64b4380983f2948a2259b",
      "note": "[Gemini answer text withheld] for patients with cardiovascular, heart-failure or kidney disease, with no first-line or initial position and no position relative to metformin (as A9 in the baseline); [Gemini answer text withheld] matched side-effect timing."
    },
    "a008032742f1d1fce09cdeb3b8add1493f1d72cb1972959ec5bdcfaa0da18a1d": {
      "code": "e5-not-first-line",
      "span": "[Gemini answer text withheld]",
      "spanSha256": "89086947dcf350cb89e3771b01079b668b5a93f7135a6811eed9989509fb4570",
      "note": "Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes."
    }
  },
  "afterWindowCoder": "Study coordinator (Claude Opus 5.5): E3 answers read in full; E5 by S11 (every paragraph with a candidate term, with the headings; the full answer opened where unclear)",
  "afterWindowCodedThrough": {
    "codedAt": "2026-10-11",
    "cyclesThrough": "2026-10-11 (UAE, Singapore)"
  },
  "e4": {
    "00716186dfd511b4d9343bf038d9477f5797e82a206628abb368032e864ffaea": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…ix months at the top dose, while Wegovy (semaglutide) achieves around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "01ba815e343955277001cb446742a448e754a1c4b4f43c0c46fb75fe7eb8e5db": [
      {
        "text": "5 to 11 pounds",
        "value": 2.3,
        "verdict": "confirmed",
        "note": "uncertain: semaglutide \"about 5 to 11 pounds\" (5 lb = 2.3 kg), compared with tirzepatide for blood sugar control and weight; no Wegovy named in the answer and a diabetes-style context, but plain semaglutide counts under S6. No kg reference within 0.5 of 2.3 kg. Decisive words: \"…semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds\"."
      },
      {
        "text": "5 to 11 pounds",
        "value": 5,
        "verdict": "confirmed",
        "note": "uncertain: semaglutide \"about 5 to 11 pounds\" (11 lb = 5.0 kg), compared with tirzepatide for blood sugar control and weight; no Wegovy named and a diabetes-style context, but plain semaglutide counts under S6. C-OCTANE-kg 4 is 1.0 kg away, so no match. Decisive words: \"…semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds\"."
      }
    ],
    "06a8b47965adfc57c6b2c549da160846fbf62b9f27b10a6df3d1667408849c1a": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "e1042fda52bcb6900f7b403f2a43a56e7c0dfb7dbc41d6cbd295c65ed83fedb0",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "0ac0553c79c88546b6c64ca2bd5eee9260a7fabd2b343c4d61885533717fcc4a": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "ae1db448c3f16476a27e636f47b3adc18d25c5a34fe771d4edcbcd2902a1b36a",
        "value": 20,
        "verdict": "confirmed",
        "note": "20-21% for Wegovy 7.2 mg; endpoint 20 matches no reference (20.7 rounds to 21). Decisive words: [Gemini answer text withheld]."
      }
    ],
    "0babaaa18da5c684a425811e223ae00275c223be1dd120ea9606f40d30b09fdf": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…ard doses, Mounjaro produces greater average weight loss than Wegovy (20.2% vs 13.7% in clinical tri…\".",
        "reason": "P2"
      }
    ],
    "0c0389ad6a09e0ad90c0dfb8ac6b7b03e66c8b575c309b3437137c0975a63742": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "67421aaa90f195b8857519754f8d310cae9982cbd314ac3e5ce3ee35bff87394",
        "value": 27.7,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, responder subgroup): 27.7% is the loss in [Gemini answer text withheld], a selected subgroup, not the mean effect. Decisive words: [Gemini answer text withheld]early re…\".",
        "reason": "M1"
      }
    ],
    "0f93f7c6d1bbe5f77175372505b00da1e6e359786caffa347c44c7f39eec6d54": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "104e8ef38fec9ffe2a5ddaf8fe16507aa25c7be28191ff92e8a960b99f3e9269": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "excluded",
        "note": "Adjudicated (coordinator): [Gemini answer text withheld] is a subgroup, not a mean effect; excluded for consistency with the [Gemini answer text withheld] items. First read had confirmed it.",
        "reason": "M2"
      }
    ],
    "10e649f8fec33716a9abd9cf86678c1ee4998a63f02926e34dd28198e4c79043": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "1117e52f8f3398902dfe8e03de21cf3c514e26bdc9fbf09e7f657d4f4d4ab60c": [
      {
        "text": "12–17%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"UAE reports indicate average losses around 12–17% of body weight with appr…\"."
      }
    ],
    "15154c6ffeb0c4e1e41ac0a444172610eccece49558974e200539605743f0a78": [
      {
        "text": "5.3kg",
        "value": 5.3,
        "verdict": "confirmed",
        "note": "uncertain: \"5.3kg in those taking semaglutide\" is the semaglutide comparator arm of the orforglipron trial (in the source trial, oral semaglutide in type 2 diabetes), but the answer does not say so; under S6 plain \"semaglutide\" is the UAE medicine. No kg reference near 5.3. Decisive words: \"…orglipron lost more weight – an average of 6.1kg-8.2kg, compared with 5.3kg in those taking semaglut…\"."
      }
    ],
    "16fad670a41fbaa7ae263b3be7b486bab442707dc8a559f1991b0cfcf5e11878": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "17960b5868feccfda1302f13d650ef2ab3b54c5840e84a010d5eeee471751231": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "17f73f41cffba22491e570dfbd58abdf0f0892170b45d88e5cf945912cda7834": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61]\".",
        "reason": "P3"
      }
    ],
    "1a0a958f0451c4b0afd2e5e3e08cd0879bf1af18c27d22afcd8b8200f7899566": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "1c8d4a1ee32a746cf50ae7793cd944c057eea1521b79f3a9b45681a143e74afc": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "1d27464e1ffafb8c4d7aa58a55e7bfdb873524485f6a221e3cdbb5fae6de34c2": [
      {
        "text": "12–15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Table column Wegovy: \"About 12-15%\"; endpoint 12 matches no reference. Decisive words: \"| Average weight loss cited in UAE sources | About 12–15% over longer treatment pe…\"."
      }
    ],
    "1f3c206acf572058eb99a80ddee9c55ad10dc0877f2f4174fd55dd8c34fd2fa2": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "201521dd7c938b34de03be3ba6ff931b266c74ea492073f7d8c02f65d05838d9": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "21c661b88a7fa2adf0d30507875dda717958d850e9be733195319b79dace0547": [
      {
        "text": "4–5%",
        "value": 4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"…t has shown some weight loss effects, the average reduction is around 4–5% of body weight, which is…\".",
        "reason": "S1"
      },
      {
        "text": "4–5%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"…t has shown some weight loss effects, the average reduction is around 4–5% of body weight, which is…\".",
        "reason": "P2"
      }
    ],
    "22ba28bbaae3b36b80b702df6929d78f306b242fc0cacc8ee945111f376f12b9": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "87574d36e48e737ca6d8ad687f47c629c93ab05661baf974323ed51f981b9602",
        "value": 20.9,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "22bf7209c51b8730b09b8033230e75b453bf80d07c30de40be12f2974effa0b5": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy produces around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "2447ce19203cc99b7f35bfd95806371622346d9a00ce81a60f9af33d60d9482e": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…s over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      },
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "2548635dd44a7e248d0db025f51120398e788e0f33a1f36a31b025f5b6371bfc": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "280e209ba8879a9c844c8de98b2721c88c6309a02984eda0ccfbb024b7073561": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "297fdd3e874edad91a1a3be505c52b8b920e729fc4298f071876ab20b4c302be": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "7296936b2c150ce7b92d5825f38bc95f4c6d2dbf8a44e084e2af9f5ac6f85310",
        "value": 3,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: [Gemini answer text withheld].",
        "reason": "P2"
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "7296936b2c150ce7b92d5825f38bc95f4c6d2dbf8a44e084e2af9f5ac6f85310",
        "value": 4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: [Gemini answer text withheld].",
        "reason": "S1"
      }
    ],
    "2c486eae0c0fd7da6ee59958ea2d0e6d722a1526ec10b9a95e766f6109b943be": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "2c8ef60ccc20e753027c7c035bb4c380900257e248166677bccfd491781ce42d": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "3063bec2f0c95474d2785a1edc07167849990a9c898c7fc806c149cc33c0df26": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "30cca17213f7ef13a04dea28b0ccca29a3548e9c291c19c38dc47196ebb8ab97": [
      {
        "text": "12-15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy (semaglutide) delivers around 12-15% weight loss over 12 mont…\"."
      }
    ],
    "316d0ff470041bd8aad16c0e5f6f1e25eb05a0fd5f9185e427aab8a7d068365d": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "a1ae6c642dc9281c8c7a7fd410204981161fea0ba4bd162483716e350ab463a4",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "31c97383ab0ba636900d181702693b529e3e412d9c2cccb8714425d45d2f7916": [
      {
        "text": "6%",
        "value": 6,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the 6% is the Saxenda (liraglutide) arm of the head-to-head, not Wegovy. Decisive words: \"egovy group lost an average of roughly 16% of their initial body we…\".",
        "reason": "P1"
      }
    ],
    "320f0e513dd2764ca36f56b3ab7667461b832d6ab3e858b4655f3fbd42a065ae": [
      {
        "text": "20.02%",
        "value": 20.02,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with W…\".",
        "reason": "P2"
      }
    ],
    "338c0920555408ced03bc2d06d45486d9669587cea17099e8c2880b4b0dba97c": [
      {
        "text": "15–20%",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S5, threshold): \"some patients exceeding 15-20%\" is an exceedance threshold for a subgroup; the row's mean is the 10-15% figure. Decisive words: \"…ide 2.4 mg) | Roughly 10–15% on average, with some patients exceeding 15–20% | Weekly injection; usua…\".",
        "reason": "M2"
      }
    ],
    "349815785d24dbe74d3cfd649a91c2873293c820d87be2b9363badfcb4ed6a16": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "36808eba1607db8a1a1a65ffd0c13fae1d5be8064ad91e40019bacae20f34047": [
      {
        "text": "[figure text withheld under the Gemini constraints; engine not recorded]",
        "textSha256": "a39d644ad9b308ab3904d0a284d0933d845583645a7b13653e86d24ece46b704",
        "value": 1,
        "verdict": "excluded",
        "note": "Excluded (S5): kg per week expected from comprehensive medical programmes, not a Wegovy mean effect. Decisive words: [answer text withheld under the Gemini constraints; engine not recorded].",
        "reason": "M2"
      },
      {
        "text": "[figure text withheld under the Gemini constraints; engine not recorded]",
        "textSha256": "a39d644ad9b308ab3904d0a284d0933d845583645a7b13653e86d24ece46b704",
        "value": 2,
        "verdict": "excluded",
        "note": "Excluded (S5): kg per week expected from comprehensive medical programmes, not a Wegovy mean effect. Decisive words: [answer text withheld under the Gemini constraints; engine not recorded].",
        "reason": "M2"
      }
    ],
    "384486ed07e0fa199d756cb7fd1b98b1f24bb153e11fdb6674444f90f952b9b2": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "3989843f34176f27209c66d3a223e004948d5ab8fd801e599631557f08ea7f5a": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "3b19248fff2656b8664c3aedc443350ee4f9fd0fb6f1bde63f4fe703abca40c1": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "679d7d5ee5a84dbc8d0299d61524d197e15e70ddf1a5d3d5ad42ec685982cfc1",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "3b631250f33b3d3558f99c4abfbaa85f45245bbdf279cfd8b24107e5cfc5a946": [
      {
        "text": "5–10%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S5/S6, lifestyle): a lifestyle, dietitian or generic-programme result or target, not attributed to Wegovy. Decisive words: \"- Expected result: Even a modest 5–10% weight loss can improve …\".",
        "reason": "P1"
      }
    ],
    "3d7d5d4ba8ad38c174841687a057418f0929f21d5245c25e9183766bae8b2738": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"… six months at the top dose, and Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "3e152c5f13d1a5f8947717083644d4fbdb64b8efd5fcce184f30e5ca57ef881e": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "3fee1083f933d33a53fddcc204c79506be552baea00dca9a9fe8ce8abe94ef00": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "41c8075823ba5189677f25ba249a17ee9f4096ea3d6020d6d46f2f95c53f89eb": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "51bb99d69dba7a5d7022f37df68c0247000ede8979d68aa3a5ba7ec274de1d69",
        "value": 13,
        "verdict": "excluded",
        "note": "Excluded (S5, individual anecdote): self-reported or testimonial individual weight loss, not a mean effect of the medicine. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "44e500b4b90453a8230a8cf872684d67ff9e94d279511b0261451bee351e9e1c": [
      {
        "text": "3–8%",
        "value": 3,
        "verdict": "excluded",
        "note": "Excluded (S5/S6, lifestyle): a lifestyle, dietitian or generic-programme result or target, not attributed to Wegovy. Decisive words: \"…rst 1–3 months: fewer cravings, improved appetite control, and around 3–8% loss for many structured…\".",
        "reason": "P1"
      },
      {
        "text": "5–15%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S5/S6, lifestyle): a lifestyle, dietitian or generic-programme result or target, not attributed to Wegovy. Decisive words: \"- Around 6 months: roughly 5–15% loss is plausible depend…\".",
        "reason": "M2"
      }
    ],
    "47692f4f92754b29a34e61bee58f5760fda0972c548ecc528474e7893b3b67be": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…e weight loss compared to Wegovy after 72 weeks, losing an average of 20.2% (22.8 kg) of body weight…\".",
        "reason": "P2"
      },
      {
        "text": "22.8 kg",
        "value": 22.8,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…t loss compared to Wegovy after 72 weeks, losing an average of 20.2% (22.8 kg) of body weight compared…\".",
        "reason": "P2"
      }
    ],
    "47e422fd5ab68f34eca4d4fc82ef351f18e518386edcc6c728e12386ad2e0b8b": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61], though th…\".",
        "reason": "P3"
      }
    ],
    "48b85f5fc49760d3dc8e4da89e4c126bdfde2af68af882f1d6400b697ba264b7": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "4938d494ffcaf20d15cbd7293db4edf091593d2f5b7cc99f8cb3029ce5cd2aad": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…% over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "4eefd5665e224a087005c818883d473237142978bc447bf2073ad580e48bbd89": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "4f91dbd07d0c68bd16dd0f7828e794f215198aaf7791a4bc14cf82f49d688a85": [
      {
        "text": "15-20%",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: \"Studies suggest an average weight loss of 15-20%\"."
      }
    ],
    "52551456c59e2fbb014ab9521b11962e4b5f986a73851d7f0fdf6304d36b0d84": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "53b653d975de1f6de370e9a4de2a45e8a3c0c5e3041f9fbadc80720d4d38118e": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S5, responder proportion): this is the share of adults reaching a 20% loss (1 in 3), not a mean effect. Decisive words: \"…with obesity or overweight with related medical conditions achieved a 20% reduction in body weight…\".",
        "reason": "M1"
      }
    ],
    "55dee66700edd770afc6112462c0479ca1585b7807610e5a5c199a8b0a716588": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "567f43142b5c7acbb237e30eb00bdaab3c1467ebe705f4114b22758a7bdbf628": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "902793ebe4c30b20e926fd02f2a3fd89b8f479f887f952f4f7a9a8446c5fde39",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "585cd1772fab6e90d25716952ec09314dea9fbbfea0072d7be5a383f985122fd": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority (\"up to\" / \"some\"), not the mean effect. Decisive words: \"People lost an average of 15% (up to 20%) body weight in a 68 wee…\".",
        "reason": "M2"
      }
    ],
    "5878e2de6cfd65bd97ad033366d8a6577cc13aed7c5e3153ac9b4e69361a46bc": [
      {
        "text": "5–10%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S5/S6, lifestyle): a lifestyle, dietitian or generic-programme result or target, not attributed to Wegovy. Decisive words: \"- Medium term: about 5–10% loss is a common practic…\".",
        "reason": "P1"
      }
    ],
    "5928eab870d16f186b9d0d8707832053a950fb6b03e25aa991a0b281c8cc6978": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "5938d2b9c3fff45a6538ea06677cbb7c2ed35df13e0f7b77bca01e7cde179a7b": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "5a17408adee0432b49939cee1c76589a5feaf954e3d8461518bfd06272168840": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…njaro at around 20% over six months at top dose, and Wegovy at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "5bd6db29a44570f8829aabd2355dc207f5c97538f0ad071dec02734166a86cad": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "5cedfa246d0904ea43884ed1d4dd9758a668501fd3a035f8d31e2829d0229db9": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "bbcc1e5282872322fb8e39e6df1bcd0e49e0970a198bebca55ce1473ed30c498",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "5ec936021dc1eb279473de1e14bcfe70a158085ea56c69c5c27693282a480e27": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "5fc94925ce41cb15210656592fe2578f456bb58cd4d873e58954f6fc4b6c9f66": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "5fdcc92db372a5bc15fe85e9de83bf3c4842b25f7b2c9e72faf85e81cd324c79": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…s over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "618ca8f9456a2ae1984a4c50a8dddbc0673a6209c58d605c551a323f5bf4b3cd": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "8fb63d72caeb74e0ddc16c03b03161640e978c7d536308948b11a2b80b2e5e2c",
        "value": 12.4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: [Gemini answer text withheld].",
        "reason": "P2"
      }
    ],
    "63a2ecff6c431a98213ffbcb1ec0293c86f66efc0f3f53ce2e06d3272c25226e": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "658898fe4100e87330583a8e18fe1537e356486c24e798b2e8d43f9e07d2102a": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "743a43af2b755e717af838b86d8f4f55fd4118f22fada1997c4969ebf743571d",
        "value": 12,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "P1"
      }
    ],
    "6ff4302d8e24d2e81ee5905777766ab55d591b31e91f02c13b8eb63451d420de": [
      {
        "text": "20.02%",
        "value": 20.02,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with W…\".",
        "reason": "P2"
      }
    ],
    "7081bee29842f6678efe5d6e810a2cf8a23222770bcec65ea7f8aa7061ed86bb": [
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "70aea0090029e69c5435dc61376005f63556430ca82612efb97a897f595ffacc": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "5dad2b9f0bb4368b5d510a686d26e0de673e4359e3caa9571bf814d104c2c274",
        "value": 4.1,
        "verdict": "confirmed",
        "note": "Genuine congress match: [Gemini answer text withheld] equals C-OCTANE-pct 4.1. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "76b99d338e43fb6c734f91d6417f0a00eed928b0b1a47ff99c2968174f0d408e": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "7b08f5348c3561d6e44457cd401178e5b378c94e19a0b693bf434da13d9f79bd": [
      {
        "text": "9.8%",
        "value": 9.8,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the 9.8% is Qsymia (phentermine/topiramate), a table row for another product. Decisive words: \"…] | Less weight loss than Mounjaro/Wegovy in cited UAE guides, around 9.8% in one table.[7] | Buyer…\".",
        "reason": "P1"
      }
    ],
    "80bd447cd0cde6b139e87727da0d8d40e78a4eca344d395fe67ef48a32ff24b3": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "80c7a6718b351d12fe392ec610727be98736753da14d9191d3bd1d2f36a69caf": [
      {
        "text": "12–15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…ight loss deliver comparable results, with studies showing an average 12–15% reduction in body weight\"."
      }
    ],
    "80c95f21c56f56f8fbeab81e010190557bb959c6197ea92754085f72f46cc970": [
      {
        "text": "11.15%",
        "value": 11.15,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…ienced greater average weight loss than those receiving semaglutide (−11.15% vs −8.83%), with more pa…\".",
        "reason": "P2"
      },
      {
        "text": "8.83%",
        "value": 8.83,
        "verdict": "confirmed",
        "note": "Semaglutide 6-month real-world mean of -8.83%; stated at two decimals, so no reference matches (8.8 is not 8.83). Decisive words: \"…ter average weight loss than those receiving semaglutide (−11.15% vs −8.83%), with more patients ach…\"."
      }
    ],
    "82867e5505227289369f51ce743c2dbfa4ae94bd62212e45159a1622a005c1ba": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "82aa93d732c4181cd21afdb859b2f4ce5486045332ccef1177089386328f1e42": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…s over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "84bb053952d5d3fdf93766b8423770cd70771fec89380cc545509fc84d2ecf6d": [
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "856cdd44a66e89ee4af2f4615a79d179fb162939d389f67f13040187e0fe225b": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "e1042fda52bcb6900f7b403f2a43a56e7c0dfb7dbc41d6cbd295c65ed83fedb0",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "86de169f46335eb12f43db42148d2492882dad8076b288b89a01f43ba270f361": [
      {
        "text": "12–15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"semaglutide delivers average body weight reduction of 12–15%\"."
      }
    ],
    "86e156b5ed2791f7abbe6247e919d07496e27d02a9139cc307aacde1e8852393": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority (\"up to\" / \"some\"), not the mean effect. Decisive words: \"… weight loss of approximately 17%, with some individuals losing up to 20% of their body weight.\".",
        "reason": "M2"
      }
    ],
    "87357a1e3e42a506c9feac23738452a72447cc08b1b7f10f849aae42cf8f6fe9": [
      {
        "text": "12–17%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Table column Wegovy: \"Approximately 12-17% in commonly cited studies\"; endpoint 12 matches no reference (17 matched). Decisive words: \"… higher—around 20% or more in high-dose studies[1][3] | Approximately 12–17% in commonly cited studie…\"."
      }
    ],
    "87d66015f1d335fe06209061b28320cdd59b19479a3c5ca9e32bb3320c17787f": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "8aeeced58c3eacf5300e69b93a2432d8d2ed07f636546ea2528c0654ab4bf557": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "0b6c7e2329cd2954df4cd94765a149d488ff77d4336be7c33ea4e26a96610873",
        "value": 22,
        "verdict": "confirmed",
        "note": "Attributed to Wegovy ([Gemini answer text withheld]); 22 matches no reference. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "8d1550a2fad8ba19f4da58164aaf1271990f43d2d8e983a0d1e46c60697518df": [
      {
        "text": "15-20%",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: \"Studies suggest an average weight loss of 15-20%\"."
      }
    ],
    "8d51de387903e5b408d71739fa04caa50cf0efac055d7c3a19b8c2a9a52f0b97": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61]\".",
        "reason": "P3"
      }
    ],
    "903de804e6f52a168953d09934335fffac0d074b8e8c1a5ab49128225e5eec4c": [
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "92110e8614d989b27441e13322d3caa42e8262a101dc79f1bd08ea528803cf84": [
      {
        "text": "4–5%",
        "value": 4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"…t has shown some weight loss effects, the average reduction is around 4–5% of body weight, which is…\".",
        "reason": "S1"
      },
      {
        "text": "4–5%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"…t has shown some weight loss effects, the average reduction is around 4–5% of body weight, which is…\".",
        "reason": "P2"
      }
    ],
    "921802152cd20be49c7876b9b3d5e495e7b5032e5a5da2c217ec51880b6ea846": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "923bf1cc5b931beb432abab6c26e0073cc8da388fe5e4df98354a258c7fac7e8": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "93ca611c8bc3d64ee70329157b53d62247900fee0311ace2c3d0f2275ac23886": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: [Gemini answer text withheld].",
        "reason": "P3"
      }
    ],
    "95bc837d3efd23d8c45a817382d551eab0a9fe12f1743eb0bae49e3a2581f69e": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "99956b91f0e6b14d112924456e530761c791d73a5eb4e728326b2e292890d78b": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority (\"up to\" / \"some\"), not the mean effect. Decisive words: \"People lost an average of 15% (up to 20%) body weight in a 68 wee…\".",
        "reason": "M2"
      }
    ],
    "9c0d613013fa5b8d379c14006e8eb5d2f0617f0c57a7bb528101210831f1d8d1": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "9c715d7387752b5d1b4da81dde7f26be7945ae078c8f95084b0e2f513532afed": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "9c9f9c1ffd69ba6bc583312a04f3203448a2815a438b50589d9e89602c87ec03": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "9dfd6b4e523a8044145b27b2dc980e30ba3f63f6987cc5bc27f99d2c9b3a4af4": [
      {
        "text": "5 to 11 pounds",
        "value": 2.3,
        "verdict": "confirmed",
        "note": "\"Semaglutide (Wegovy)\" effects \"about 5 to 11 pounds\" (5 lb = 2.3 kg); no kg reference within 0.5. Decisive words: \"…semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds\"."
      },
      {
        "text": "5 to 11 pounds",
        "value": 5,
        "verdict": "confirmed",
        "note": "\"Semaglutide (Wegovy)\" effects \"about 5 to 11 pounds\" (11 lb = 5.0 kg); C-OCTANE-kg 4 is 1.0 kg away, so no match. Decisive words: \"…semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds\"."
      }
    ],
    "a2ab60f50120caa97bdc439501a33a059d3be1c4fd5e8e5f944d54c1e42722a9": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "a315f3114006862e5928e155b1c04bb8685b5f5290fb812def016e8c77aadb35": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…s over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      },
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "a3681c193f283b335994bf10699e3f11b4033a0ffd22c3cacd1a7360cf3d851b": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "a44b0bad3ff5e9bb3e626255e5b94b51eb4ad2dc9ce5e346d2aa64b089f088fe": [
      {
        "text": "5%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S5/S6, lifestyle): a lifestyle, dietitian or generic-programme result or target, not attributed to Wegovy. Decisive words: \"…n-led programs can produce meaningful but more modest results, around 5% body-weight loss in UAE …\".",
        "reason": "P1"
      }
    ],
    "a4998c86283126238f9212fc61b1d213b6812f949714b7c0f0e645cbd026b95c": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "a6baef1c4c1691237a166d4df312f884cc878102ad128b110a8dd57e1471a0a4": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "a80a6faf85d649fe6f673519853ea64725de528abe4daf2adcd145ac6bb34ca3": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "a995a6b6824e82a5e2aa00f2225b49e740135531ca538257e1f8f26656ee218d": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "aafc5004f69d38b4a1a7e43fd5797c1864feb0b051410e6a347c0c89dee65cd0": [
      {
        "text": "20.02%",
        "value": 20.02,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with W…\".",
        "reason": "P2"
      }
    ],
    "ab9c3e39dfe73ef06d22425872cf906310ce24037966b8fef4f409481da2f79f": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "d1e1d77ec17c3b55a3a1c4fd8458c91ece57671e1e49964e8549eb7d3f10e741",
        "value": 3,
        "verdict": "excluded",
        "note": "Excluded (S5): a median change in BMI (adults), under a low diabetes dose of semaglutide, not a mean body-weight change for Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "O1"
      }
    ],
    "abd244b1b3b053e8a679f03b7437d61d57a46e47b6fae1fe4bcd7ff6cb00656d": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy achieves around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "ac906862ce3759c1ff7e9b9c5a826c47528cdfc644cf364618907710ef9701dd": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "ad1643356841a77d1a4ddf19a828c6a933cb40966b20d612519ca37c56cbb230": [
      {
        "text": "12-15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Semaglutide's results range from 12-15% weight reduction\"."
      }
    ],
    "add37089ee3af5fdbfb8f42233643a7f26e7166a9e49f1bbc088ade8d475f554": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "aea18b90d95b13c9bec3a779db3379067199288f83ab9ba444e146ea37ec6196": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S5, responder proportion): this is the share of adults reaching a 20% loss (1 in 3), not a mean effect. Decisive words: \"…with obesity or overweight with related medical conditions achieved a 20% reduction in body weight…\".",
        "reason": "M1"
      }
    ],
    "b1134fc811772174470e4f9402f38d7e6eaa7bf4292d96a3f340afd39b4ee7f1": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "b2c1805bf4382f82723da9ae4c2e3029139e862e213157fb8858c0ff3922bec4": [
      {
        "text": "6.1 kg",
        "value": 6.1,
        "verdict": "confirmed",
        "note": "uncertain: \"6.1 kg for semaglutide users\" after 12 months in a real-world cohort (HbA1c also mentioned, so possibly a diabetes cohort); plain semaglutide counts under S6 and no kg reference is near 6.1. Decisive words: \"…o initiated semaglutide, with tirzepatide users losing 10.2 kg versus 6.1 kg for semaglutide users.\"."
      }
    ],
    "b48e526bce763429bf0de76dd9eae9f9a70d8becd6586d5a9eea3b3d59b876b2": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "b52214d5c6e13f37ccc6b661479cc82026c5ba23bf2b8caf43ffb053efe1e6a1": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…ht loss over six months at the top dose, while Wegovy achieves around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "b5cf321bc81d6bb5251b761b165398f80564a647bb16a01fedc30d63eddc9024": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…weight loss than semaglutide (Wegovy) in the main head-to-head trial: 20.2% vs 13.7% over 72 weeks.[…\".",
        "reason": "P2"
      }
    ],
    "be8e01facefd58279787014105005d517ff0374f8bef679b0f60d038d1cfc98a": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "bf0b689decb3b747961536fd596d0f9836d0af8cb20bbd928275412ecbd24ec7": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "c0216b4167666bafdc300bfdb3d34d0ba7b7651ad60ca9d92904bf70f6273b6d": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "dc934fe30a942bca07b4c288b4b3e48aa79a717d6db2b586553cd2416dc8b9b8",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority ([Gemini answer text withheld] / [Gemini answer text withheld]), not the mean effect. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "098b1367dcb7540a7ebca4a822a8b7c7d1805596bb9bb53db24b034a2dc0c24d",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "P1"
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "276dac8a33fdf74f8b2d34debe82a6f2b80a964702d844e313d24ee976ca0c71",
        "value": 6.8,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "c232838b0097a6fc6f305fb99febf711b4535c8ebfea63d22f423dec9e1c54e4": [
      {
        "text": "4-5%",
        "value": 4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"- Significantly better results (13.6% vs. 4-5% weight loss)\".",
        "reason": "S1"
      },
      {
        "text": "4-5%",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: \"- Significantly better results (13.6% vs. 4-5% weight loss)\".",
        "reason": "P2"
      }
    ],
    "c340c10f5df87fe2a6f70751287dd4be8dfad93eb44ebc18b59a361ae7dc87de": [
      {
        "text": "[figure text withheld under the Gemini constraints; engine not recorded]",
        "textSha256": "234d0e73855ae7bf477734cbd4c1e50d56d5d00af3edb4bc8ddbdf44e8d5c8de",
        "value": 12,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: [answer text withheld under the Gemini constraints; engine not recorded].",
        "reason": "P3"
      }
    ],
    "c459ead2398aaf4e6e280be41907438a93808550250fed3b5f7e63d95e82db79": [
      {
        "text": "12-15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…t loss over six months at top dose, while injectable Wegovy is around 12-15% over 12 months—new pills…\"."
      }
    ],
    "c45a503b2cc274113081ad32a526e9e2d187d09d4961fc41e86d3880871d8b12": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "c481747f8d68046fef3c5fe8e3fcc447ef9ec51b6a3a2e60db852e3eef21bae8": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "c4d7e111419b25d00751960bd14fda63c673c876b0a9fad51b368a35a9ac3bf3": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "c5dc73b3489d521fae05e266360388a806d1f69ee7e420279dd4c25f87530227": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "c649d351c5303ab526808cb1130410fb3f297fdc9bbec023a27b89dfbfc2ae69": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "ae1db448c3f16476a27e636f47b3adc18d25c5a34fe771d4edcbcd2902a1b36a",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy 7.2 mg [Gemini answer text withheld]; endpoint 20 matches no reference (20.7 rounds to 21). Decisive words: [Gemini answer text withheld]."
      }
    ],
    "c9bf942bb6a6c3f3acbd8f0fda4a70e5ffbd5de081d051b550f2500edb6e17f5": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…g at around 20% over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when pair…\"."
      },
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "uncertain: the paragraph is cut off after \"and 11.1% with oral\"; oral Wegovy already has its own 16.6%, and 11.1% is the Foundayo 72-week figure elsewhere in the same set, so it is attributed to the other oral product. Decisive words: \"…2.5% with Zepbound, 20.7% with Wegovy HD, 16.6% with oral Wegovy, and 11.1% with oral\".",
        "reason": "P1"
      }
    ],
    "cbe810e7285cfaf484e24ccf52fa24d700e44e58aa9249e28719de02edf4a42e": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "cc827dfca02c06f41209012fb7be395b22cb302a21554bc59147064652e55708": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…s over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when pair…\"."
      }
    ],
    "ceda715a29ef820330c0fa85ae3de3421352612ba4e6673276abe1c20265115a": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…20% average weight loss at the top dose, compared to Wegovy at around 12 to 15% over 12 months\"."
      }
    ],
    "d11588b92434046382017603f964a6b9c9faec7450b90353c0b8d3698c47b519": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"… weight loss, Mounjaro generally outperforms Wegovy in trials (around 20% vs 12 to 15%).\".",
        "reason": "P2"
      },
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"… loss, Mounjaro generally outperforms Wegovy in trials (around 20% vs 12 to 15%).\"."
      }
    ],
    "d32734fbf3cc87b255e6d5d895a3c29476330677e9ed423c6d1c62fad5246d68": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "d640d570afb7abe03f89b03305ff59a14b9480a6c1b4fac9082f3b85eb01bdc7": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy achieves around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "d66aa16892f607ed20dd00ec124417224d96a43b2cbada926cec3579292500ec": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "5cd355525f87ead8f713ea5c1efcf310fae8eee9b64318d019b2c3ffe0b811f5",
        "value": 29.9,
        "verdict": "excluded",
        "note": "Excluded (S5, individual anecdote): self-reported or testimonial individual weight loss, not a mean effect of the medicine. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "d6fabcd96132b985c6b0e5d74c875779b4bddb6f4acb1f3fdc8e019255b28020": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "a45f0889a9b6d39be6ce97b7800895731962a04b05382e45d9ead817311f456e",
        "value": 17.3,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "P1"
      }
    ],
    "d7643df371077ab7f2c3378944204bfe667780d346cd151751ed230268e6ad7f": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "d79760c09df66cd5d7d886d2bb2afaa77d47db0615ea1f16a3ef216a98307834": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "dc934fe30a942bca07b4c288b4b3e48aa79a717d6db2b586553cd2416dc8b9b8",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: [Gemini answer text withheld].",
        "reason": "P3"
      }
    ],
    "d8b4e8dd2d70b449fbe30971ee5d3dcb789e2a7456d343d0f370273e851af290": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "da323f4d4ffa708db905f08c99b7768cd371ce78e3d68ca6f0380b5ba7acc85f": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "276dac8a33fdf74f8b2d34debe82a6f2b80a964702d844e313d24ee976ca0c71",
        "value": 6.8,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "db879a45f112e685608bac9b6f06b999d9755667e9031f006a291e75405bb1aa": [
      {
        "text": "22.5%",
        "value": 22.5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…linical trials, people taking Mounjaro 15mg weekly lost an average of 22.5% of their starting body w…\".",
        "reason": "P1"
      }
    ],
    "dc6acf8da33b4fa90a37a04cb3d2f9ae1a5ecfb7499a7b0c0a81a1fd91af9fed": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61]\".",
        "reason": "P3"
      }
    ],
    "dddf2776b71abe8ffe595418612673bb9d279731a8b9e53471f70c958c7e7c9f": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "dc934fe30a942bca07b4c288b4b3e48aa79a717d6db2b586553cd2416dc8b9b8",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority ([Gemini answer text withheld] / [Gemini answer text withheld]), not the mean effect. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "743a43af2b755e717af838b86d8f4f55fd4118f22fada1997c4969ebf743571d",
        "value": 12,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the sentence sits in the Ozempic entry (semaglutide as the molecule of Ozempic, diabetes product), not Wegovy. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "e1b0ffcd84a942b4d272c606ca95644396906b836dffc3209831b6709ca9a1c3": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"It produces approximately 12 to 15% weight loss over 12 mont…\"."
      }
    ],
    "e2c0f5d7d4e01c85c96842cfc040b16b4d735588a73d240dae8ea1d59d601670": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "5dad2b9f0bb4368b5d510a686d26e0de673e4359e3caa9571bf814d104c2c274",
        "value": 4.1,
        "verdict": "confirmed",
        "note": "Genuine congress match: [Gemini answer text withheld] in the Wegovy entry equals C-OCTANE-pct 4.1. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "e365d131327271a5c9b6b9fa06f79fc75bbb421884f1198e6367551d2a7da26c": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "e56848e3dffe19ae034ce5c1ac59cf389f7985ffca0f267a83c2b0512639d617": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "e56bcf4ee1b2f76a7df48fe1d7ecea731cf58da8435a94265bf9f89468757d9b": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority (\"up to\" / \"some\"), not the mean effect. Decisive words: \"People lost an average of 15% (up to 20%) body weight in a 68 wee…\".",
        "reason": "M2"
      }
    ],
    "e6d7daa8be5992d6a7265565743b216c2240503869a13ca34d2d89607f876da0": [
      {
        "text": "12.4%",
        "value": 12.4,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…ffective—oral Wegovy reduces weight by up to 16.6% vs. competitors at 12.4%\".",
        "reason": "M2"
      }
    ],
    "e7221a0589d6d9f8f70e1da523d388cf29b6770f4a093b61122f335c3895262b": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…an Wegovy/semaglutide in the head-to-head trial cited in the sources: 20.2% vs 13.7% over 72 weeks.[…\".",
        "reason": "P2"
      }
    ],
    "e77f9d09b7b54fe2828508e22f70f5a180463d519bb3f9601044d52734a99cea": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "dc934fe30a942bca07b4c288b4b3e48aa79a717d6db2b586553cd2416dc8b9b8",
        "value": 20,
        "verdict": "excluded",
        "note": "uncertain: Excluded (S5, ceiling or subgroup, not a mean): the figure is the top end for a minority ([Gemini answer text withheld] / [Gemini answer text withheld]), not the mean effect. Decisive words: [Gemini answer text withheld].",
        "reason": "M2"
      }
    ],
    "e897bfb6b5e8b2219b9cdf175f90975c6f0bba8bb2212b7fa0b441778463a888": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "e90ab6d8aff3a807ae31cf2bd5a41f0039040dd99652347b88a24aea1a378a0e": [
      {
        "text": "15-20%",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: \"Studies suggest an average weight loss of 15-20%.\"."
      }
    ],
    "ecb023029e9b85f72c996049729bf9414cd3d4710f047a22b449205b0a7ab935": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "ef360e04509c13c90a9573e7392a3ee5de72e6938720e8d1fce2135037ce5454": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "f00dca3ef66d876fb7b3af0f6732039d8d0ae67a6b67fd4548fb1f0e655cbd00": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…-head trials, adults taking tirzepatide (Mounjaro) lost an average of 20.2% of their body weight whi…\".",
        "reason": "P1"
      },
      {
        "text": "8.3%",
        "value": 8.3,
        "verdict": "confirmed",
        "note": "Semaglutide (Wegovy named in the previous sentence) 8.3% at 12 months; no reference rounds to 8.3 (8.8 is a different value). Decisive words: \"…ults on tirzepatide lost about 15% of their body weight compared with 8.3% for semaglutide.\"."
      }
    ],
    "f0694e57c2d3d0a7225b05880b9a81315d71eee53cb300aa9e1b3863c56eb6ce": [
      {
        "text": "12–15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"…tide 2.4 mg — Wegovy | Large randomized trials generally show roughly 12–15% average weight loss over…\"."
      }
    ],
    "f2939bebd53ca493ea43b84bc643fbc25577d7300ac6221f4632e80a468b1c33": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "f3f1afef57dbc1bd15fde73a39c5de449a70adbce655ff4037537d6e1bd85fb3": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "f775fceb91d18805c8f590d0bc6fbb29e366cd125aff164509612692cfb0c537": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by a class or several products (semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), or the oral GLP-1s Foundayo and Wegovy), so it is not a Wegovy-only effect. Decisive words: \"[sentence S2 of withheld page P61]\".",
        "reason": "P3"
      }
    ],
    "fa0814f893121eb4d863bcb8d799787f69d78eb723a42d8ed7145a33fe2a04f0": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this figure is the tirzepatide/Mounjaro/Zepbound result, not Wegovy's. Decisive words: \"…er average weight loss than Wegovy at 72 weeks in adults with obesity—20.2% vs 13.7%\".",
        "reason": "P2"
      }
    ],
    "faf07a6927deec7c544f94bf5817301771948f8c1cca6c2a184011c0fe81ff32": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "fb94cc2bbee9f7649a84b0f2267201d7a101c4919c43d2a018933bd9b898afa5": [
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"…govy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over 72 weeks for the st…\".",
        "reason": "P2"
      }
    ],
    "fbedf912aa1b0b6e50ec32196ed237a582fc96474de47f5498308e110c0ee65b": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "fcfc3975f4c34077572d1a4c41a41546f051d287a21160005f229ea7df6eac80": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "8eb2532b6e08a02146d9834b411ffeec60f66bedc5c22d2e4c6de1c2841451e3",
        "value": 5,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: [Gemini answer text withheld].",
        "reason": "P2"
      },
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "8eb2532b6e08a02146d9834b411ffeec60f66bedc5c22d2e4c6de1c2841451e3",
        "value": 7,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Rybelsus (oral semaglutide, type 2 diabetes) weight effect, a comparator to Wegovy. The script's congress match to OCTANE 4.1 (where flagged) is a false match: OCTANE is Wegovy oral switchers. Decisive words: [Gemini answer text withheld].",
        "reason": "P2"
      }
    ],
    "fd4d8da7cda32c7fcb00540125c71945e9e8f391c93a30e48b21aad23bf3e535": [
      {
        "text": "12 per cent",
        "value": 12,
        "verdict": "confirmed",
        "note": "uncertain: sentence is about \"GLP-1 receptor agonists, such as semaglutide\" with no product in the sentence; S6 fallback (subject of the line = semaglutide) makes it the UAE medicine. Class-level wording may argue for exclusion. Decisive words: \"…icate patients may achieve an average body weight reduction of around 12 per cent over time.\"."
      }
    ],
    "ffede0333052d2c25840859b9c52932ac38d023ca9279d9ae34ea200ee20e127": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "3732c82a843f69bd5611819dd0d891c4ac11306a1ef1a630fdaf95b622db8551",
        "value": 20,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 20% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ],
    "3031fdd2328cd9d05298a371609d474cd8cb7cd4d7a985a6f541b5b540d8bb49": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by the class it follows, semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), so it is not a Wegovy-only effect (as the same sentence in earlier cycles). Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "90ed20803adf7012aba45888277fdf26801b82a5532c5ba1692919fd802dc3c8": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by the class it follows, semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), so it is not a Wegovy-only effect (as the same sentence in earlier cycles). Decisive words: \"[sentence S2 of withheld page P61]\".",
        "reason": "P3"
      }
    ],
    "35a16bf0113913fb26957e70bb42b15250e673e7d27ea9ffd7ca04f8fa911ad3": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by the class it follows, semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), so it is not a Wegovy-only effect (as the same sentence in earlier cycles). Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "8a3d486903718899bb20183aa59ec42633d3e1af3812c3d3bf7dc2ea2fa07a04": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by the class it follows, semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), so it is not a Wegovy-only effect (as the same sentence in earlier cycles). Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "0661c60596a129b090d0cab69f7c53c08312d74f669567ff5584e5cf07803513": [
      {
        "text": "[figure beside a withheld sentence of page P61]",
        "value": null,
        "verdict": "excluded",
        "note": "Excluded (S6, joint figure): the figure is owned jointly by the class it follows, semaglutide (Ozempic, Wegovy) AND tirzepatide (Mounjaro), so it is not a Wegovy-only effect (as the same sentence in earlier cycles). Decisive words: \"[sentence S2 of withheld page P61].\".",
        "reason": "P3"
      }
    ],
    "0fd6c5f0fce103dad01b16bfaa6ec0b2f7b2453a7a81b28494f5932fc1d70c03": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry/sentence; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"while Wegovy (semaglutide) achieves around 12 to 15% over 12 months\"."
      },
      {
        "text": "11.1%",
        "value": 11.1,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the Foundayo (orforglipron) figure, set against Wegovy's separate figure. Decisive words: \"compared with 11.1% over 72 weeks for the strongest Foundayo dose\".",
        "reason": "P2"
      }
    ],
    "d07fefbef7c6d62116b1ef0f202de0e9b54cfaf2b0c801bd58f2e3c4ee3c20dd": [
      {
        "text": "12 to 15%",
        "value": 12,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry; no reference value rounds to 12% at the stated precision, so it stays no-source. Decisive words: \"Wegovy delivers around 12 to 15% average weight loss over 12 months\"."
      }
    ],
    "e6904aac65a8fc80c808afa39c9085d266f73d3b7b09180aa7ccd066e3e550b5": [
      {
        "text": "20.2%",
        "value": 20.2,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): this is the tirzepatide (Mounjaro) arm of SURMOUNT-5, set against semaglutide's 13.7%. Decisive words: \"tirzepatide (Mounjaro) achieved 47% greater relative weight loss than semaglutide, with 20.2% versus 13.7%\".",
        "reason": "P2"
      }
    ],
    "82324070e298932ebc7b09a454ee2cf03c12bc7fa8d59a0aa63d3c022a53617e": [
      {
        "text": "6%",
        "value": 6,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the 6% is the Saxenda (liraglutide) arm of the head-to-head, not Wegovy (reason code as the same sentence on an earlier cycle). Decisive words: \"compared to about 6% in the Saxenda group\".",
        "reason": "P1"
      }
    ],
    "eac14107a8db999f368075880604e34ca6697b6afc58462d9466e0a56b35681e": [
      {
        "text": "20%",
        "value": 20,
        "verdict": "excluded",
        "note": "Excluded (S6, other product): the 20%+ is Mounjaro's figure, set against Wegovy's separate 16.6%. Decisive words: \"Need maximum weight loss results (20%+ vs. 16.6% for Wegovy)\".",
        "reason": "P2"
      }
    ],
    "2115ad0b1de993780e03d332827025d1200a307279e0d3806b8d10c68deb1ec1": [
      {
        "text": "[Gemini figure text withheld]",
        "textSha256": "97b24cab3d48e47c11cff2598b6c26d69a6d5a834d270d8711c2e3662c310e90",
        "value": 5,
        "verdict": "confirmed",
        "note": "Wegovy mean-effect figure under the Wegovy entry; no reference value rounds to 5% at the stated precision, so it stays no-source. Decisive words: [Gemini answer text withheld]."
      }
    ]
  },
  "e4Checker": "D4 first read by a separate agent (same model family) of every no-source and congress figure; coordinator adjudicated every uncertain item, all six congress items, and random samples of 11 exclusions and 30 no-source confirmations (one overturned: id 125). A figure repeated verbatim in one answer carries one check. The 12 figures from the 11 Oct UAE cycle were read by the coordinator directly, against the verdicts given to the same sentences in earlier cycles.",
  "e4ReasonCodes": {
    "P1": "different product, molecule or intervention",
    "P2": "comparator effect attributed to the target product",
    "P3": "joint or class-level figure without valid brand attribution",
    "M1": "responder proportion mistaken for a mean effect",
    "M2": "maximum, subgroup or illustrative result mistaken for a mean effect",
    "S1": "incorrect congress-source association",
    "O1": "other S5 exclusion (BMI value, price)",
    "U1": "insufficient evidence to verify attribution"
  }
}